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ABSTRACT
Quantitative cancer imaging is an emerging field that develops computational techniques to acquire a
deep understanding of cancer characteristics for cancer diagnosis and clinical decision making. The recent
emergence of growing clinical imaging data provides a wealth of opportunity to systematically explore
quantitative information to advance cancer diagnosis. Crucial questions arise as to how we can develop
specific computational models that are capable of mining meaningful knowledge from a vast quantity of
imaging data and how to transform such findings into improved personalized health care?
This dissertation presents a set of computational models in the context of malignant brain tumors—
Giloblastoma Multiforme (GBM), which is notoriously aggressive with a poor survival rate. In particular,
this dissertation developed quantitative feature extraction approaches for tumor diagnosis from magnetic
resonance imaging (MRI), including a multi-scale local computational feature and a novel regional habitat
quantification analysis of tumors. In addition, we proposed a histogram-based representation to investigate
biological features to characterize ecological dynamics, which is of great clinical interest in evaluating tumor
cellular distributions.
Furthermore, in regards to clinical systems, generic machine learning techniques are typically incapable
of generalizing well to specific diagnostic problems. Therefore, quantitative analysis from a data-driven
perspective is becoming critical. In this dissertation, we propose two specific data-driven models to tackle
different types of clinical MRI data. First, we inspected cancer systems from a time-domain perspective.
We propose a quantitative histogram-based approach that builds a prediction model, measuring the differ-
ences from pre- and post-treatment diagnostic MRI data. Second, we investigated the problem of mining
knowledge from a skewed distribution—data samples of each survival group are unequally distributed. We
proposed an algorithmic framework to effectively predict survival groups by jointly considering imbalanced
distributions and classifier design. Our approach achieved an accuracy of 95.24%, suggesting it captures
class-specific information in a challenging clinical setting.
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CHAPTER 1
INTRODUCTION
Diagnostic medical imaging has been recognized as a core health care sector for cancer diagnosis and
therapy planning over the past decade. Conventional image-based evaluation from qualitative assessment
is largely done using the clinical judgment of experienced radiologists. In contrast, quantitative evalua-
tion, relying on computational techniques, provides an objective tool to mine knowledge from radiographic
images, potentially leading to the discovery of underlying disease characteristics. From such quantitative
analysis, the resulting vast quantities of data offer a rich source of clinically useful information to make more
informed decisions for patient care. The whole procedure has the potential to revolutionize the traditional
tumor MRI interpretation and necessitates the use of computational techniques for the goal of precision
medicine. Exploring quantitative information from such imaging data is becoming a key to developing
quantitative methods to improve cancer diagnosis, risk assessment, and therapy planning.
Quantitative models are particularly valuable since they are able to provide objective information for a
better understanding in early cancer detection as well as improved diagnosis. Advanced quantitative frame-
works are necessary for achieving a quantitative understanding of the physiological status of cancer, and
are likely to play a fundamental role in guiding patient management in the future [1]. The core idea of this
dissertation is to develop a series of quantitative methods for malignant brain tumor diagnosis using clinical
MRI. The proposed approaches aim to use rigorous mathematics to evaluate radiographic images, gaining
evidence-based knowledge to seek a deep understanding of cancer and facilitate clinical decision making.
Specifically, we aim to extract and evaluate quantitative information obtained from clinical brain tumor
MRI, building predictive models that automatically distinguish clinical outcomes (e.g., survival groups) as
shown in Figure 1.1. To quantitatively model brain cancer dynamics, we deal with two challenging aspects
as primary research objectives:
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Figure 1.1: Building predictive models for improvement in cancer diagnosis.
• Knowledge Discovery: Since conventional understanding of brain tumor MRI is largely constrained
to intratumor semantic structures including necrosis and active cells, there is growing interest in ex-
ploring novel imaging biomarkers to further improve diagnosis and biological interpretation. A fun-
damental question is how do we integrate clinical knowledge and medical imaging to measure brain
tumor response?
• Predictive Modeling: Machine learning is essential in developing image-guided predictive models.
With the emergence of a large variety of clinical data, it remains an open question how data science
techniques, such as machine learning and data mining, help build effective clinical decision-support
systems for better patient care.
1.1 Malignant Brain Tumors
We study the most primary malignant brain tumor Glioblastoma Multiforme (GBM) from MRIs. The
GBM remains a uniformly fatal disease with a reported an incidence rate of 4.74 to 8.57 per 100,000 men and
women per year in United States [2]. Despite substantial progress made in genetic and molecular domains
for analyzing malignant brain tumors, there are still challenges for effective understanding of brain tumor
heterogeneity. Meanwhile, radiological heterogeneity of GBM in clinical MRI is widely recognized; GBMs
present remarkably diverse variations in terms of visual appearance and shape. The variability gives rise to
opportunities for modeling tumor dynamics and developing effective therapies.
GBMs present significant diagnostic challenges which are ripe for treatment with computational meth-
ods and the standard method of diagnosis is brain biopsy, a dangerous and invasive procedure. Glioblas-
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tomas have highly heterogeneous features which include central and diffuse necrosis, rapid cellular growth
and diffusive infiltration of surrounding brain tissue. The median survival time for GBM patients is 12-15
months with tri-modality therapy [3, 4] with the most significant improvement in therapy being an addi-
tion of 6 weeks to overall survival with the addition of the alkylating agent temozolomide to surgery and
radiation [5].
1.2 Why Consider Brain Tumor MRIs?
Medical imaging plays an important role in the diagnosis and management of brain tumors and has
a significant impact on surgery, radiation planning, and chemotherapy [6]. Quantitative evaluation from
medical image data enables objective outputs and reproducible analysis, which are vital for large-scale
disease diagnosis. It is worthwhile to learn from such data to measure tumor response, guide therapeutic
planning, and ultimately lead to better patient care. In this dissertation, we analyze different brain tumor MRI
datasets to gain insights into the quantification of brain cancer. Popular medical imaging techniques include
Positron Emission Tomography (PET) [7], Computerized Tomography (CT) [8], and Magnetic Resonance
Imaging (MRI) [9]. These imaging methods not only provide clinical information but also are a rich source
of data which can serve as the inputs for computational models. In this study, we focus on brain tumor MRIs
and briefly present the main reasons to use quantitative image analysis and outline the primary motivations
of the work.
• Diagnosis: In brain tumor diagnosis, MRI is used for physicians to detect tumor location, tumor
grades, and many other anatomical attributes which are critical for corresponding therapeutic planning
for patients. Meanwhile, MRI has been broadly applied in the clinic, and there has been an increasing
usage of clinical imaging data over past decades [5].
• Noninvasiveness: A notable property of MRI is that it serves as a noninvasive tool for cancer diagno-
sis, which is in contrast with genomic analysis that requires invasive biopsies or surgeries to extract
specific gene information.
3
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Figure 1.2: A typical diagram of quantitative imaging analysis in brain tumor MRI.
• Time-sequence Function: In brain tumor diagnosis, only MRI scans are able to track tumor progres-
sion diagnosis across time, providing valuable information for monitoring tumor staging status both
before- and after-treatments.
• Comprehensive Assessment: MRI provides a comprehensive view of tumors, including spatial loca-
tion, extent of the disease, and many different cellular phenotypes, which enables a pathway to realize
a quantitative analysis to extract meaningful information to guide cancer treatments.
1.3 Developing Predictive Models for Brain Tumor Imaging
Predictive image-guided brain tumor diagnosis is a systematic process (as shown in Figure 1.2) that
requires various types of computational techniques. In general, the design of the underlying decision-making
process can be varied for different diagnostic problems. In this dissertation, our central focus is placed on
two important components: quantitative feature extraction and classification.
• Brain Tumor MRI Sequences: Inputs are sequences of tumor MRI obtained according to the image
acquisition protocol. Different MRI modalities can be considered according to the specific research
goals. In this step, image preprosesing is usually required (e.g., image registration and normalization)
to prepare the standardized data for the following analysis.
• Tumor Segmentation: The tumor area is viewed as a region-of-interest (ROI), including both en-
hancing and non-enhancing tumor regions. With a segmentation procedure, we are able to obtain
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the target—entirely separated tumor region from healthy brain tissues. It is also possible to obtain
multiple sub-regions for advanced analysis.
• Feature Extraction: Quantitative feature extraction incorporates various computational models to ob-
tain meaningful information from tumor pixels. Due to the large variability across tumor phenotypes,
there is an emerging need to investigate robust feature descriptors to effectively quantify brain cancer
staging and treatment response.
• Feature Selection: It is defined as a functional process to alleviate the burden of computational com-
plexity and overfitting the data from a high-dimensional feature. Feature selection (or feature learning)
is designed to acquire an efficient and compact representation (reduced number of features) of the raw
feature set.
• Classification: Once having computational features for data samples (e.g., patients), a machine learn-
ing classifier is built for a classification/prediction task. It is worth noting that, to obtain positive
results, general classifiers need be tailored to specific diagnostic problems. Prediction outcomes can
be viewed as evidence to guide clinical treatments.
• Diagnosis: Objective evaluation can be complemented with human experts opinions. Combining au-
tomated prediction results and professional radiologist opinions, the diagnosis decision can be made
for patients. Also, objective evaluation can be used to explore underlying characteristics, provid-
ing quantitative evaluation on risk assessment and likelihood estimation on disease status, which are
particularly valuable due to the limits of human knowledge.
Our studies integrate brain tumor radiology with data science. Therefore, this dissertation performs
a thorough evaluation of developing quantitative models to find answers to a variety of specific research
questions which are of great interest in a clinical setting and computational science as follows:
• Can malignant brain tumors of the Glioblastoma Multiforme (GBM) type be consistently divided into
specific radiologically defined habitats based on combinations of images sensitive to blood flow and
edema? Does the distribution of these regions vary among tumors in different survival groups?
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• Survival analysis is always a crucial aspect in cancer diagnosis and prognosis. What kinds of specific
imaging biomarkers can be discovered from brain tumor MRI to classify clinical survival groups?
• In light of evolution, it is a priority to inspect the cancer system from a time-domain perspective since
it explicitly tracks the dynamics of cancer variations. Can temporal information derived from clinical
MRI be predictable based on combinations of MRI modalities for brain tumor patients?
• In a real clinical setting, we always confront different clinical data distributions, which can be a
difficult topic in data science. A challenging question is how can we deal with a skewed clinical
dataset with unequally distributed clinical classes?
1.4 Contributions
In response to these challenges and seeking a deep understanding of malignant brain tumor dynamics,
we propose several conceptual and technical components as the primary contributions of this dissertation.
1.4.1 Quantitative Image Feature Representation
We develop a family of approaches for quantitative feature extraction from MRI to represent patients
using computer vision and image processing techniques. The proposed quantitative features are categorized
by different scales: local, spatially variant, and a holistic histogram approach as follows.
• Local Computational Image Features. We propose extracting multi-parametric local image fea-
tures from MRI. Inspired by oncology where the local environment appears critical to maintain cell
survival—the “niche” region can direct cell proliferation and differentiation—we investigated local
visual patterns using using MRI (contrast T1-W, FLAIR, and T2-W modalities). To fully capture
tumor heterogeneity, multi-scale parametric feature descriptors were realized by observing different
scales of local neighborhood structures in voxel space. Local pattern statistics obtained from tumor
images are valuable due to the fact latent “niche” areas may play a crucial role in cancer evolution.
We examine the proposed approach with an application of survival group prediction: patients were di-
vided into 2 survival classes (i.e., short and long term groups), which reflect distinct and group survival
characteristics. From extensive experiments, our results found that 1) statistical local visual features
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can be used to obtain accurate survival group prediction with GBM patients; 2) the post contrast T1-W
modality that measures blood flow variation made the most contribution for prediction.
• Regional Features—Spatially-explicit Habitats. Following the idea of cancer evolution and ecology,
we applied a concept—“habitats [10]”— to quantify spatial variations of tumor heterogeneity. It is
well known that, in the oncological lexicon, typical expressions describing brain tumor structures—
such as “necrotic”, “enhancing”, and “edematous”—are commonly used to describe brain tumor se-
mantic structures. However, most of these descriptions are subjective, lacking a quantitative mea-
surement, which restrains the interpretation for cancer therapy. Furthermore, traditional radiological
features assume tumors were heterogeneous in terms of visual appearance, shapes and edges. These
features are typically present in the absence of “spatial variations”, where multiple distinct tumor
sub-regions can be created to observe and characterize tumor evolution and hence further help the
diagnosis. To address this, we applied a concept of “tumor habitats [10]” as prognostic biomark-
ers in describing spatially homogenous (or distinct) regions of brain tumors. We built the proposed
model based on the idea that observable regional variations are essential to help us explore tumor
heterogeneity. The proposed approach consists of two main steps: 1) tumor sub-regions obtained
from the intratumor segmentation; 2) a spatial mapping scheme from multi-modality MRI imaging
(T1-W, FLAIR, and T2-W MRI slices). In other words, a tumor region is initially segmented into high
and low signal groups and then a joint mapping scheme is used to consider the correlation between
different input modalities. Our findings allowed us to visually observe regional brain cancer dynam-
ics. Regional variations—reflecting different scales of molecular or tissue-level dynamics—present a
novel perspective for understanding the underlying biological evolution.
• A Pair-wise Histogram-based Approach. We proposed a histogram-based analysis that is useful to
explore cancer dynamics. The proposed approach provides information about the underlying cancer
evolutionary dynamics. Since ordinary 1-D histograms (a single channel input) consider a statistical
frequency from one input modality, a potential correlation between different scans is entirely ignored.
We propose a 2-D pairwise histogram representation by superimposing two different MRI sequences
from the same tumor. Thus, resulting histograms have the advantage of capturing the statistical vari-
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ance from dual modalities. Our results show that clinical imaging can be used to gain insight into the
evolutionary dynamics within tumors. Furthermore, combinations of sequences from standard MRI
data can define distinct regions within the GBMs, and this can be considered as a potential patient
specific prognostic biomarker.
1.4.2 Clinically-driven Learning Models
To enable an integrative analysis of MRI data with clinical outcomes, it is imperative to consider clinical
information as prior knowledge. Traditional machine learning models are typically incapable of generalizing
well to specific disease prediction problems. This dilemma necessitates consideration of specific clinical
knowledge in the learning models. In this section, we discuss data-driven learning models to tackle the
challenging clinical MRI data.
• Imbalanced Learning for Clinical Survival Time prediction. Accurate computer-aided prediction of
survival time for brain tumor patients requires a thorough understanding of clinical data, since it
provides useful prior knowledge for learning models. However, to simplify the learning process,
traditional settings often assume datasets with equally distributed classes, which often does not reflect
a typical underlying distribution. In this study, we investigate the problem of mining knowledge
from an imbalanced dataset (i.e., a skewed distribution) to predict survival time. In particular, both
an imbalanced distribution and classifier design are jointly considered: 1) We used the Synthetic
Minority Over-sampling Technique to compensate for the imbalanced distribution; 2) A predictive
linear regression model was adopted to learn a pair of class-specific dictionaries, which were derived
from reformulated balanced data. We tested the proposed framework using a dataset of 42 patients
with GBM tumors whose scans were obtained from the cancer genome atlas (TCGA). Experimental
results showed that the proposed method achieved 95.24% accuracy.
• Histogram-based Approach using Time-sequence MRI. Brain tumor heterogeneity remains a chal-
lenge for probing brain cancer evolutionary dynamics. In light of evolution, it is a priority to inspect
the cancer system from a time-domain perspective since it explicitly tracks the dynamics of cancer
variations. In this paper, we study the problem of exploring brain tumor heterogeneity from temporal
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clinical MRI data. Our goal is to discover evidence-based knowledge from such temporal imaging
data, where multiple clinical MRI scans from GBM patients are generated during therapy. In particu-
lar, we propose a quantitative histogram-based approach that builds a prediction model to measure the
difference in histograms obtained from pre- and post-treatment. This study could significantly assist
radiologists by providing a metric to identify distinctive patterns within each tumor, which is crucial
for the goal of providing patient-specific treatments.
1.5 Dissertation Organization
Chapter 2 discusses the background of related topics for the dissertation, including brain tumor MRI
assessment, quantitative feature extraction, and machine learning. Chapter 3 discusses the proposed multi-
scale local computational feature extraction from MR images. In Chapter 4, we develop a framework for
quantifying explicit regions on brain tumor MRIs. Chapter 5 introduces a pair-wise histogram model to
explore cancer dynamics in view of an ecological system. Chapter 6 introduces a prediction model that used
a time-sequence MRI (both pre- and post-treatment scans were considered). In Chapter 7, we developed a
clinically-driven learning model targeting imbalanced clinical data distributions. Chapter 8 summarizes the
dissertation and outlines the directions for the future work.
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CHAPTER 2
BACKGROUND
We review brain tumor MRI and related image-guided computational techniques for cancer analysis.
The new research frontier aims to translate predictions of likely outcomes into cancer diagnosis, patient
stratification, and treatment guidance. As a cross-disciplinary endeavor, there is an emerging need to con-
sider translational knowledge in different fields. Figure 2.1 illustrates several important specialties: 1) Ra-
diology (e.g., radiographic analysis and diagnosis); 2) Computer Vision (e.g., image feature extraction); 3)
Data Mining (e.g., feature selection); and 4) Pattern Recognition (e.g., classification). The numerous factors
render the combinatorial analysis a challenging task. The central focus, therefore, is placed on integrating
different domains into specific computational models that aim to achieve diagnostic precision and improve
the quality of treatment.
We primarily put emphasis on specific topics in quantitative feature extraction and the development
of predictive models from tumor MRI. We also shed light on a variety of quantitative feature approaches
to handle a large array of numbers extracted from imaging data. More importantly, we see a clear need
to collectively study computational cancer imaging due to its fast-evolving development utilizing multiple
disciplines. Thus, we aim to bridge the gap between brain tumor radiology and computational models,
providing a gateway for researchers from both communities to propel quantitative cancer imaging research.
To glean insights from different domains, the following sections present the general concepts of brain
tumor MRI assessment as well as related techniques. We present studies about several important computa-
tional components in image analysis as its core: 1) Quantitative Feature Extraction. Feature extraction and
representation is a key component to obtain minable knowledge from tumor MRIs; 2) Feature Learning. We
discuss techniques in feature selection and feature reduction for acquiring meaningful reduced feature sets
from high-dimensional data, which are crucial for predicting clinical outcomes; 3) Learning Paradigm. To
handle different decision-making tasks, specific learning schemes are needed to take advantage of feature
10
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Figure 2.1: Multiple disciplines intersect in quantitative cancer imaging. Cross-domain knowledge integra-
tion will help guide clinical treatment decisions and ultimately lead to the goal of improving health care.
inputs. For the purpose of better predicting different clinical outcomes, we discuss three fundamental types
of machine learning models including supervised, unsupervised, and semi-supervised learning. Finally, a
description of open research challenges in developing quantitative models in cancer research is presented.
2.1 Brain Tumor MRI Assessment
Clinical brain tumor imaging offers a noninvasive technique to characterize observable phenotypic tu-
mor evolution and is an indispensable tool for tumor detection and diagnosis. Image analysis is built on
the central hypothesis that tumor imaging reflects underlying dynamic biological phenomena such as gene
expression patterns, tumor cell proliferation, and blood vessel formation. In this section, we review different
imaging modalities used in brain tumor diagnosis and give a brief overview of malignant brain tumor types.
2.1.1 Brain Tumor MRI Modality
Tumor heterogeneity in radiographic characteristics is well recognized in cross-sectional clinical imag-
ing as shown in Figure 2.2. Different modalities of MRI are able to delineate various biomedical properties
more effectively than other modalities (e.g., CT can only show differences in electron density). The resolu-
tion available in the various sequences of MRI provide clinical imaging data which is used to observe and
characterize changes in tumor biology throughout treatment. As examples of phenotype data, we have post-
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(a) High-grade tumors
(b) Low-grade tumors
Figure 2.2: Tumor MRI examples. Contrast T1-weighted tumor scans with bounded marked boxes from
TCGA dataset.
contrast T1-weighted slices which show bright enhanced regions (high signal intensity) within the tumor
due to the intravascular injection of gadolinium chelates as contrast agents. Through this, necrosis and the
active region of tumors can be differentiated. The T2-weighted sequence captures the amount of water in
the brain which is used to both delineate different tissue types and also pathologic fluid balances, which can
be further differentiated by fluid attenuated inversion recovery (FLAIR) sequences which provide a better
distinction between edema and tumor [21]. Diffusion-weighted MR imaging sequences offer a powerful
tool for the characterization of tissue architecture. Based on the diffusion of water molecules, diffusion
MR shows invisible structural tissue pathways [22], advances in which have led to assessment of differing
water diffusivity in separate tissue types. The apparent diffusion coefficient (ADC) has been correlated with
tumor cellularity and tumor grade [23] [24]. ADC can be calculated on a pixel-by-pixel basis, allowing
the generation of a parametric map that reflects the diffusion influence. Some less common MR techniques
have been employed as well for various specifications in brain tumor imaging analysis, including perfusion
12
Table 2.1: Brain tumor types with examples
Category Tumor Examples Typical Characteristics
Grade I [11], [12], [13] Pilocytic astrocytoma
Slow growing rate, occurring mostly in chil-
dren.
Grade II [14], [15] Low-Grade Astrocytoma
Slow growing rate with ambiguous tumor
boundary.
Grade III [16], [17] Anaplastic Astrocytoma Grows more aggressively than Grade II.
Grade IV [18], [19], [20]
Glioblastoma multifome
(GBM)
Grows rapidly and spread aggressively.
imaging, proton density-weighted image (PDWI), fast spin echo (FSE), short tau inversion recovery (STIR),
etc. More introductions of specialized modalities can be found in [25].
MRI modalities are efficient for detecting brain abnormalities. It is noted that contrast enhancement
with the proper amount of contrast agent doses is especially helpful for the delineation of brain tumors [25],
because the zone of glioma cells described by enhancement after high-dose gadolinium is likely to give
a better estimation of microscopic tumor extent. Also, a normal brain is not enhanced due to the blood
brain barrier (BBB). The enhanced imaging provides more accurate differential delineation of tumor, earlier
detection of small metastatic lesions, and allows for a better observation of the post treatment effects and
recurrence after therapy.
2.1.2 Taxonomy of Malignant Brain Tumors
To determine the specific treatment for tumors, the type of brain tumor must be initially identified.
According to different origins, brain tumors are divided into primary (70%) and secondary (30%) [26]. A
primary brain tumor originates from the cells within brain, while a secondary or metastatic brain tumor starts
somewhere else in the body and then moves to the brain. There are over 120 types of brain tumors [27],
most of which were named for the cell type of origin. The most common primary tumors of the brain—
Gliomas—derive from the glial lineage. In addition, to better observe tumor progression, based on the
World Health Organization (WHO) system classification [28], primary brain tumors are categorized into
four grades: Grade I and Grade II are slow growing and are classified as Low-grade tumors; Tumors of
Grade III and IV grow more aggressively and are called High-grade tumors (Figure 2.1). Primary brain
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tumors cause an average reduction in life expectancy of 20 years in cancer patients. The most aggressive,
and common form of primary brain tumor is grade IV gliomas, termed glioblastoma [29].
Although enormous efforts have been made on characterizing brain tumors that might help determine
patients with differing prognoses and response to specific therapies, the cause of brain cancer remains un-
known, and only a small proportion of risk factors may appear to account for few cancers: the exposure under
radiation condition, genetic conditions, and family history [30]. Thus, how to prolong the patients survival
time becomes an important research direction, since expected survival time analysis and prediction could po-
tentially lead to better treatments and prognosis. In the analysis of survival rate, several important prognostic
factors are considered: the variety of histology, clinical trials, age at diagnosis, and race [26] [27]. There are
several fields that could affect the outcomes: brain tumor prognosis, symptom management, chemotherapy,
and clinical trials. More details can be found in [31]. Overall, technical advances have been applied towards
analytical diagnosis for the detection of the brain abnormality. However, the development of a quantitative
and reproducible computer-aided framework is still at an early stage.
2.2 Quantitative Image Feature Extraction
Quantitative image feature extraction is a key step towards building image-guided models for predictive
cancer diagnosis and prognosis. A primary motivation for feature extraction is that informative features
could capture the meaningful biological information and potential discriminative patterns enabling better
medical decisions. As a result, methods of extracting quantitative features from medical imaging have
gained increasing interest in biomedical informatics. This section summarizes several types of features that
can be extracted. In addition, it describes a number of computer vision techniques that are increasingly used
in quantitative cancer imaging science.
The extracted quantitative features from medical images are a set of quantities describing the “object”
(e.g., a tumor region). In the literature, there are papers on designing automated algorithms to extract and
analyze medical imaging data [32] [33] [34] [35]. These models explain a complex evolution of disease
progression as a function of a biological process [8] or they build on theories of image-based mathematical
reasoning. Current approaches can be conceptually divided into two types: image descriptors based on
computational algorithms and biologically interpretive feature extraction.
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2.2.1 Radiomics—Computational Image Features
The emerging field of quantitative feature extraction from cancer imaging—Radiomics—has shown its
promise to revolutionize traditional cancer diagnosis. Radiomics defines a series of high-throughput tech-
niques to extract large amounts of features from radiological images [36]. It is scientifically based, relying
on rigorous mathematical approaches to evaluate radiological images and translate extracted knowledge to
improve healthcare for patients. With different mathematical models, various feature extraction models are
proposed to describe visual characteristics including shape, appearance, color, motion, etc. In general, such
computational image features are closely related to computer vision, as opposed to approaches coming from
a biologically plausible perspective. Because approaches in Radiomics quantitatively describe the visual
contents to acquire meaningful representations, these features have a potential to allow for a large-scale
reproducible evaluation, which is particularly promising with the explosion in the amount of imaging data
nowadays. We review representative approaches that aim at linking clinical imaging and computer vision
techniques. For instance, Lowe et. al [37] [38] proposed the Scale Invariant Feature Transform (SIFT),
which is an important image descriptor in the current computer vision field, with extensive vision-based
applications such as image matching [37] and object recognition [39]. In particular, Zhuhadar et al. [40]
employed the SIFT feature descriptor for the brain disease classification problem.
Based on the scale of feature extraction, typically there are two extraction strategies including local and
global approaches. A local invariant feature is an image pattern which differs from its immediate pixel
neighborhood [41]. As a typical example, Local Binary Patterns (LBP) [42] has been widely shown to be
a robust statistical local image descriptor; it is efficient due to its computational simplicity and consistency
with any monotonic gray level change [43]. In contrast, a global feature emphasizes the overall composition
of an image. The GIST computational model [44] was initially designed for the recognition of visual scenes
and has been successfully extended to a number of machine vision tasks. All these types of features are
essentially derived from computer vision techniques. In fact, the feature extraction process is closely cou-
pled with the automated visual applications, such as object segmentation, recognition, and image attribute
interpretation. Accordingly, when we focus on the medical imaging, these applications are applied to more
specialized fields. They can be directly described as tumor/tissue segmentation, disease classification, and
clinical interpretation. Computational image features play a key role of robust visual perception. In brain
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cancer analysis, the efficient usage of feature representation often depends on the medical data (e.g., MRI),
and the associated target (e.g., lesion detection). In [35], they used pattern recognition methods for distin-
guishing different types of brain tumors, such as primary gliomas from metastases. They used registered
T1-weighted, T2-weighted, and FLAIR data. Image features included shape, image intensity, and voxel-
wise Gabor filter features. In general, several properties of a strong image feature descriptor for quantitative
tumor analysis can be summarized as:
• Distinctiveness: the proposed descriptor is able to capture the unique patterns in tumors for different
clinical classes.
• Extensiveness: the proposed descriptor holds the potential to be applicable for related applications.
• Robustness: the proposed descriptor is stable under different imaging acquisition parameters and
invariant to different image resolutions.
Regional variation—beyond local and global scales of feature computation—means distinctive regions
and their correlations within the tumor, which can be critical in decoding brain cancer dynamics. In a recent
initiative, [32] proposed a novel concept of “habitats” to characterize tumor evolution, where a tumor is
quantified into distinctive regions, and the study suggested computed regional features were able to distin-
guish clinical survival groups. In fact, limited works at the regional level (e.g., [45]) have been proposed in
medical imaging applications. In computer vision, such an idea can be similarly associated with mid-level
feature representations, which refer to computation on a structured part of an image. For instance, the Bag-
of-Word (BoW) model [46]—a type of mid-level feature—has been successfully extended to image feature
representation. The entire model mainly incorporates two steps: codebook construction from local patches
of an image and the description of an image by a statistical quantification on the codebook.
2.2.2 Biologically Interpretive Features
Biologically interpretive features transfer recognized radiology knowledge into a quantitative format.
From a pathological perspective, these types of features are disease-specific. The extracted biological fea-
tures are normally used to observe disease dynamics, and they are also beneficial for clinical therapy and
treatment. Therefore, understanding of disease characteristics is strongly required to propose this type of
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feature. A significant barrier is that it is challenging to translate quantitative measurement into biological un-
derstanding. Zikic et al. [33] defined context-aware features for the high-grade glioma tumor segmentation
problem. More concretely, they explored the intensity relationship between voxels, and then investigated the
visual appearance context. The parametric features suggested the feasibility of capturing context informa-
tion from brain tumors. Also, we found that image-guided MRI features provide a means to investigate the
underlying model at the cellular or organ level, such as observing the spatial variations and temporal evolu-
tion of tumors. Zhou et al. [47] defined a spatial distance measurement to quantitatively explore the problem
of brain tumor heterogeneity. The proposed spatial distances were used to measure the variations between
biologically-defined tumor regions, and a practical application for survival time prediction was designed to
show the predictive power of these features. Also, the study [48] found that early temporal changes and
spatial heterogeneity during radiotherapy in heterogeneous regions of high and low perfusion in gliomas
might predict different physiologic responses to radiotherapy.
Biologically interpretive features are correlated to corresponding data modalities. As discussed in the
prior section, different MRI modalities come with their clinical imaging protocols. As a result, a differ-
ent selection of modalities may directly affect biological interpretation and feature computations. This is
important in the context of biology to characterize tissue-level dynamics, and may be beneficial to under-
stand the potential biology of diseases. For example, Jing et al [49] used the Apparent Diffusion Coefficient
(ADC) histogram for the early prediction of drug treatment response for glioblastoma multiforme (GBM).
In the study, diffusion weighted and T1-weighted data were separately used for the ADC computation and
tumor segmentation process. It is noted that the ADC concept here was to show that the diffusion process is
complex in biological tissues and reflects several different biomedical mechanisms [50].
Statistical estimation can also be used for brain cancer data interpretation. The study [51] used statis-
tical histogram features for the classification of glioma grades. It created relative Cerebral Blood Volume
(rCBV) maps from the MRI data using standard kinetic models. Feature vectors were formed by computing
the rCBV histogram descriptors: histogram mean, median, variance, kurtosis, skewness, and peak height.
Similarly, feature extraction could also be viewed as a statistical modeling process. The study [49] applied
a Gaussian Mixture Model (GMM) to estimate the ADC histograms to evaluate tumor treatments.
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Long-term research challenges remain as to how we can develop quantitative approaches which are
capable of transforming phenotypic observation into actionable knowledge, leading to improvement in dis-
ease understanding and patient treatment planning. Image signals obtained from brain tumors naturally
exhibit various geometric shapes, appearances, and voxel-wise variations with associated underlying bio-
logical characteristics at the molecular, tissue, and organ levels. The variety gives rise to the need for a
well-organized feature extraction framework. A promising direction is fusion of different types of features
that can be jointly considered to boost the feature extraction process. Also, to yield reliable performance,
it is an important task to further validate results from the collective data sources. With increasing volumes
of clinical imaging data, there are a wealth of opportunities to explore novel feature representations for
different diagnostic problems.
2.3 Feature Selection and Feature Reduction
2.3.1 Feature Selection
Feature selection is defined as a functional process to obtain a subset of features by removing irrelevant
or redundant features, while optimally preserving the original or intrinsic information [52]. It differs from
feature reduction that seeks a reduced feature set through a transformation process. In recent years, medical
data has become increasingly prevalent in both amount of data and number of features. Large amounts of
MRI or functional MRI data are collected for patients during the process of clinical diagnosis before and
after treatments. However, with the increasing number of features in an implicit high dimensional space
(up to hundreds or even thousands of features), the predictive performance obtained from machine learning
models may drop dramatically, which is commonly known as “curse of dimensionality” [53]. Therefore,
it is imperative to propose algorithms to effectively reduce the data dimensionality. There are extensive
works on feature selection [54] [55] [56] to decrease overfitting and improve the generalization performance
and efficiency of learning tasks in data mining. As a result, the benefits of applying feature selection in
brain tumor MRI imaging are clear: 1) selection of an optimal subset of features may boost the predictive
accuracy; 2) elimination of large volumes of redundant features significantly reduces the computational
complexity. A more comprehensive survey on feature selection can be found in [57].
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In general, feature selection algorithms fall into two types: filter and wrapper methods. The fundamental
differences are in the feature ranking measures [58]: filter methods eliminate redundant features to produce
the most promising subset before learning commences; wrapper methods embed learning algorithms into the
selection procedure. When the number of features become very large, filter models are usually chosen due
to their computational efficiency [52], however wrapper methods often enable better prediction performance
than filter methods, since the use of re-sampling techniques (e.g., cross validation) potentially improves
the performance generalization. For example, filter methods evaluate the goodness of the selected features
through various criteria, including: mutual information [59], Fisher score [60], statistical t-test [61], etc.
Among these models, Relief-F [62] is well known for its practical success in a variety of applications. The
main idea of Relief-F is to iteratively estimate a feature’s importance based on its ability to separate inter-
and intra- classes samples in a range of nearest neighbor samples. The wrapper method uses a learned model
to assess the usefulness of selected subset features. The study [63] proposed a wrapper model based feature
selection using the Support Vector Machines (SVMs) classifier. To improve computational efficiency, the
wrapper model often comes with two greedy search strategies: forward selection and backward elimina-
tion [58]. Forward selection starts with no features and creates subsets iteratively by adding features until
the best performance is achieved; backward elimination begins with the entire feature set and eliminates
the least important feature(s) sequentially to improve the final results. In the study of brain tumor imaging,
[32] proposed a ranking model for texture features from brain tumor MRIs. The model was implemented
by means of a simple mean nearest neighbor criterion to iteratively test on a single feature, and an optimal
upper bound accuracy was achieved by a leave-one-out cross validation. Another study of brain tumor clas-
sification [35] used a two-tailed t-test measurement to explore the discriminative power of each individual
feature.
An emerging trend in feature selection is to incorporate a sparse learning technique into subset feature
selection. By imposing the L1 norm regularization, a recent study [64] proposed an unsupervised feature se-
lection model called Multi-Cluster Feature Selection (MCFS), incorporating a spectral embedding technique
(i.e., multi-cluster structure of data is well preserved) and a sparse optimization procedure in an L1-norm
least squares formulation (i.e. feature weights are given by a sparse learning scheme). As we know, a com-
mon weakness of some feature selection approaches is the limitation in dealing with huge datasets. Sun et al
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proposed a model which was capable of showing competitive results on cancer data and handling thousands
of features doing selection in minutes on a personal computer. A merit of that work is to decompose the
global nonlinear problem into a set of local linear ones, and then learn feature relevance globally through
a sparse learning framework. Similarly, a unified feature selection framework [65] used generalized sparse
regularization and showed its superiority over state-of-the-art models.
2.3.2 Feature Reduction and Manifold Learning
Feature reduction is a decomposition technique that transforms a high dimensional data into a lower
dimensional space, which is an active area for medical imaging applications for subspace analysis and visu-
alization. One of the most well-known algorithms is principal components analysis (PCA) [66] which seeks
linear combinations of the original variables so that the derived variables capture maximal variance [67].
There are also several approaches to reduced feature representation with different mathematical models in-
cluding: Linear Discriminant Analysis (LDA) [68] which seeks feature reduction by a Fisher solution, i.e.,
maximizing the difference in inter-class variances while minimizing intra-class variances; Singular Value
Decomposition (SVD) [69] uses singular values derived from a matrix decomposition technique, gener-
ating a compact representation of data samples; Neighborhood Component Analysis (NCA) [70] learns a
Mahalanobis distance in a k-nearest neighbor (KNN) graph.
Manifold learning is a powerful subspace learning technique that relies on data’s intrinsic geometrical
properties, converting high-dimensional data into a low-dimensional space. Due to its effectiveness in in-
terpreting data in the reduced subspace, manifold learning has been applied to different medical imaging
applications, ranging from MRI image segmentation [71], multi-modal image registration [72], biomarker
discovery in brain MRI imaging [73]. More recently, Loc Tran et al. [74], applied manifold learning tech-
niques in the brain tumor progression prediction task and found that the progressed region and normal
tissue are well separated in a low dimensional space. Similarly, the study [75] proposed a manifold learning
approach—spectral prototype extraction—to tackle the brain tumor classification problem.
Owing to the large volume of biological data in quantitative cancer imaging, feature computation through
selection-based and reduction-based approaches has become an indispensable tool for extracting meaning-
ful knowledge from large arrays of features. However, it is without doubt that, understanding the biological
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meaning of extracted imaging features, and how the image information in a low dimensional space cor-
relates biological meaning are tasks of rising importance for researchers. It is worth noting that, despite
feature selection/reduction algorithms converging during a learning stage, the computed “optimal” feature
subsets are by no means guaranteed. After testing these feature subsets, models should be further retested
on different sources of data as needed to more precisely capture feature importance. In addition, learning
correlations of features and finding definitive explanations of disease-related features will provide the pos-
sibility of accessing potentially important features and facilitating clinical decision-making. In other words,
the development of transforming features useful for prediction into clinical understanding is still an open
issue for the long-term goal of translational healthcare.
2.4 Learning Paradigms
Machine learning models are principled approaches for developing predictive models from different
types of image features. The predicted outcomes provide an objective reference to aid detection and diag-
nosis of abnormalities by physicians. For example, in the biomedical field, machine learning is essential
for numerous applications, including image-guided therapy (e.g., cancer prognosis), abnormality detection
(e.g., lesion segmentation), and clinical outcome prediction (e.g. survival time prediction). Before applying
learning models, a specification for the task, as prior medical knowledge, is needed so that the methods
can be well designed. Based on the proportion of the available labeled data, several fundamental learning
schemes are presented: supervised, unsupervised, and semi-supervised learning. In supervised learning, the
goal is to learn from a set of trained samples with known class labels, and to predict the unknown patterns
from large and noisy data sets [76]. Conversely, unsupervised learning finds the natural structure from data
without having any prior labels. As a hybrid approach, semi-supervised learning uses only a small amount of
training data. The unlabeled data samples, instead of being discarded, are also used in the learning process.
More details are discussed in following subsections.
2.4.1 Supervised Learning
Supervised learning, one of the most used learning schemes, has been widely applied in a large variety of
settings [32] [33] [77]. Before a detailed review of specific algorithms, it is critical to have an understanding
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of the concept of supervised learning. The learning process is conceptually divided into two parts. At a
training step, data samples ( ~X, ~Y ) with available feature values in feature vectors ~X and class labels in
~Y are used to “train” a classifier—obtaining a set of parameters from a mathematical function to predict
the label by ~Y = F ( ~X) [78]. At a testing step: the learned classifier is used to predict the labels of
testing samples. As a result, evaluation of classifier performance is measured by a comparison between the
predicted labels and true labels. For example, suppose we are given a feature vector ~X , which consists of a
certain number of feature values, the role of a supervised classifier is to output a predicted class label that
the example is likely to belong to. It is noted that the selection of classifiers depends on the properties of the
classifier, such as convergence properties and modeling assumptions [79]. In other words, suitability and
generalization are the key factors to examine classifiers performance.
2.4.2 Unsupervised Learning
Without knowing any prior identifiers (or labels) of data, unsupervised learning algorithms are proposed
to group the data according to their mutual similarity. For example, Clark et al. [80] introduced a knowledge-
based unsupervised fuzzy clustering for the brain tumor segmentation task—tumor and healthy intracranial
regions can be grouped using this clustering algorithm and a rule-based expert system. Another related work
can be found in [81]. The recent explosion in clinical imaging results in an onerous task of manual image
annotation. Therefore, there is a growing need to explore scalable clustering algorithms for large medical
imaging data.
2.4.3 Semi-supervised Learning
Semi-supervised learning is designed specifically for problems where it is difficult to obtain class la-
bels for samples (e.g., the estimation of tumor progression during the surgery period). In other words,
semi-supervised learning can, to a degree, overcome the limitation of conventional supervised learning—
incapable of analyzing data without enough labeled data. Semi-supervised models have shown their effec-
tiveness for computer-aided diagnosis in the brain tumor field. For example, study [82] predicted states of
brain tumor prognosis using a semi-supervised learning model. With less than 35% of the available class
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labels (“dependent but conscious” or “dead”), a discriminative analysis was done on a collection of 86
patients using the limited labels of patients with aggressive Glioblastomas.
2.4.4 Evaluation Metrics
Cross validation is broadly used for the evaluation of classification/prediction algorithms in practice. A
proper selection of a cross validation approach may help with the design of the predictive framework and
benefit the parameter selection and provide more optimal outputs. In general, the dataset is often divided
into different subsets: K-fold cross validation or random sampling schemes. For a K-fold cross validation,
the data is randomly with or without stratification broken into K folds.. At each round, K-1 folds of data are
treated as the training data, and one remaining fold is treated as the testing set. Leave-one-out is a special
case of the K-fold testing: at each round, only one sample from the dataset is selected as the testing set;
all remaining samples are viewed as the training samples. Random sampling creates a training set which is
formed by randomly sampling of entire dataset without replacement; the samples remaining are treated as
the testing set. Choosing the number of folds can affect performance evaluation: a larger number of folds
usually lead to a smaller bias of the true error values than a small number of folds. Once cross validation
is conducted, taking a binary class setting for example, classification results for a particular method can be
formed into a confusion matrixMc×c for a task with c classes. The following metrics are used for evaluating
the performance of a classifier for two classes. True Positive (TP) is the number of positive instances that
were predicted as positive. True Negative (TN) is the number of negative instances that were predicted as
negative. False Positive (FP) is the number of negatives instances that were predicted as positive. False
Negatives (FN) is the number of positive instances that were predicted as negative.
Accuracy =
TP+TN
TP+TN+FP+FN
(2.1)
Also, there are alternative metrics to complement the accuracy. With different emphases on the outputs,
the precision (positive predictive value) and recall (true positive rate) are defined as follows.
Precision =
TP
TP+FP
(2.2)
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Recall =
TP
TP+FN
(2.3)
In addition, the F-measure combines the precision and recall in terms of a harmonic mean:
F-measure = 2× Precision× Recall
Precision + Recall
(2.4)
G-mean =
√
TP
TP+FN
× TN
TN+FP
(2.5)
The metrics are defined for binary classification problems, but they can be extended to a multi-class
problem with n classes (n>2). In many medical diagnosis applications, Receiver operating characteristic
(ROC) analysis is an another tool to evaluate the performance of the algorithm. Also, the associated Area
Under Curve (AUC) is an important parameter to determine the generalization ability of the method. These
are defined for 2 class problems, but can be used in multi-class scenarios. For unsupervised learning, in
the application of the unsupervised clustering, Normalized Mutual Information (NMI) [83] is a widely used
criterion for the purpose of clustering algorithm evaluation.
2.4.5 Case Studies in Brain Tumor Diagnosis using MRI
We review selected prediction approaches for brain tumor MRI data. In particular, these works focus on
using different machine learning models for tumor status classification. We further discuss limitations and
ongoing needs for predicting different clinical outcomes.
• Classification of Tumor Types. Zacharaki et al [35] investigated a multi-class classification problem,
which included different histological groups: gliomas, metastases, high grade (grade III, and grade IV)
and low grade (grade II) neoplasms. The aim of this study was to assess the discrimination ability of
standard MRI images usually acquired in most clinical facilities. Following the traditional supervised
learning setting, the multi-parametric framework included: brain tumor identification, raw intensity
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and texture based features extraction, reduction to a small set of effective features by applying feature
selection methods and machine learning methods for classification purposes.
• Specific Tumor Tissue Discriminative analysis. The study [84] used image-guided MRI features for
differentiating radiation necrosis from recurrent tumors. It is worth pointing out that differentiating
radiation necrosis from tumor recurrence is a critical unsolved problem in glioblastoma multiforme
(GBM) patients undergoing chemoradiation therapy. A one-class SVM classifier was used for the
radiation necrosis class only, which avoided the difficulties in the collection of negative samples (re-
current tumor).
• Stratification of Brain Tumor Response. Joanna et al [85] examined the individual risk of brain cancer
relapse or progression after radiotherapy. They built a Naive Bayes classifier to estimate individual-
ized treatment. An 84% prediction accuracy was obtained from a dataset of 142 patients, where the
spectrum of diagnosed tumor types ranged from meningiomas (good survival prognosis) to glioblas-
tomas (worse survival prognosis).
• Survival Time Prediction. Zhou et al [32] connected heterogeneity of brain tumor with clinical sur-
vival time. The survival time was divided into binary classes based on tumor progression times: Fast
Progression and Slow Progression. They found that local visual features could be used to obtain ac-
curate survival time predication with GBM patients. By cross validation, the average accuracy was
93.75% for a dataset of 32 cases.
• Detection of Metastatic Brain Tumors. The study [86] proposed a 3-D template matching based
nodule detection algorithm for the goal of identifying a high percentage of metastatic brain tumors in
MRI. This work provided a tool for the radiologist to identify and detect the location of high suspicion
for nodule presence.
• Imaging Features and Generic Information. Imaging features and generic information give us a pos-
sible fusion analysis. Gutman et al [87] conducted a comprehensive analysis on GBM using visual
imaging features as well as the correlated gene expression information. A dataset collected from the
TCGA portal [88] was used for testing. Two concerns were investigated: 1) survival, tumor size, and
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morphology; 2) imaging features and genomics. The study showed that imaging features can be com-
bined with genetic mutations and gene expression subtypes to provide an insight into the underlying
biologic properties of GBM subsets.
Despite the fact that different prediction models have been proposed for measuring tumor response, sev-
eral important factors are addressed for improved quantitative imaging evaluation. First, in the applications
discussed above, current prediction models are mostly targeted at high-level class labels, in contrast, limited
studies considered the specific sub-groups (e.g., accelerated or non-accelerated treatment prediction) which
probably are of strong clinical interest for providing direct treatment suggestions. As a result, for exploring
clinically-guided predictions, we need a collaboration between computer scientists and radiologists so that
clinical data sharing and inter-area knowledge transition can be realized. Second, although cross-validation
is commonly applied to evaluate performance of the proposed models, it remains uncertain how well the
prediction outcomes from the studied data can be inferred or expanded to samples from different sources.
There few available public datasets in the literature restrict comparisons from peer researchers. Addition-
ally, the explosion of clinical data necessitates a key requirement (if medically feasible)—standardization
across different areas. More precisely, it is a priority to develop integrative analysis as the core for handling
large-scale heterogeneous clinical data from various data acquisition protocols, policies, and regulations.
Therefore, evaluating the performance from different sources (such as hospitals and institutions) is becom-
ing an essential step to investigate the robustness of the proposed prediction models and disseminate a system
that operates across image platforms.
2.5 Research Challenges
Substantial progress has been made towards tackling brain cancer research. Numerous computer-aided
systems and computational models have been proposed to facilitate the process of cancer diagnosis, prog-
nosis, and therapeutic planning. The area is actively moving forward in a large number of ways where
cross-disciplinary analysis is a key: both data analysis through computing and development of radiology
techniques give rise to a number of opportunities. However, technical challenges remain for extending re-
search discoveries to real clinical practice. To envision trends in the ongoing research in the field, several
challenges and opportunities are summarized in the following.
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2.5.1 Quantitative Feature Extraction
Quantitative feature extraction is the central focus for predictive image-guided cancer diagnosis. With
the increasing size of clinical imaging data in terms of both the number of patient cases and feature dimen-
sions, novel techniques are required for finding feature importance among a large number of quantities. We
discuss two representative techniques that have shown promise in the development of data-driven models.
First, a suggested trend is to investigate sparse structured learning models. A recent study [89] proposed
a sparse learning model for the brain disease classification problem—a small subset of features can be ob-
tained from a large set by sparse regularization. The original idea [90] has received remarkable attention
and been successfully extended to different settings such as biological gene study [91] and rodent brain seg-
mentation [92]. The new model provides an alternative way to tackle high dimensional inputs and achieve
strong results for various prediction tasks as well. Second, Deep Learning is becoming a new research
frontier which has been shown to outperform conventional approaches by extracting high-level features
from well-designed sophisticated hierarchical convolutional network layers [93]. Deep architectures can
be valuable in representing disease-specific features by allowing good generalization and providing statis-
tical strength through multiple level abstractions. In [94], a deep learning feature representation has been
proposed to tackle brain disease classification. In this study, quantitative features were extracted from a
stacked auto-encoder network for exploring a latent feature representation (e.g., non-linear feature corre-
lations). Although it remains an open question as to how we can design layers (or hidden units) within
the network structure that are robust for a particular image-guided analysis, the heart of deep learning—
discovering meaningful compact patterns via hierarchical networks—is a promising direction for medical
imaging applications, since the problem of hand-crafted feature extraction and onerous image preprocessing
can be largely alleviated.
2.5.2 Clinically-driven Machine Learning
With ever-growing interest in integrating machine learning with quantitative cancer imaging, a technical
focus is converging on clinical-driven machine learning, which opens up a new space for researchers. In
addition to finding a predictive solution through traditional learning approaches, the emergence of new
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challenges in brain cancer quantification requires more precise formulations. Several useful and suggested
learning schemes are discussed in the following.
• In brain cancer diagnosis, it is obvious that we may not have access to observe the full data distribution
of potential risk factors; instead, we can learn from limited but related samples to further investigate
the problem. In this scenario, Transfer Learning [95] can be used to learn from related tasks to improve
the performance of learning algorithms. The goal of transfer learning is to leverage previous learning
and experience to more efficiently learn related concepts [96]. In fact, the study of biomedical data
involves rich information from different domains: various imaging modalities, gene information, and
clinical records. Transfer learning can handle related tasks, especially when it is difficult to learn from
a certain domain.
• Active Learning [97] involves human experts (e.g., radiologists) selecting “curious samples” to im-
prove the performance of learning algorithms (i.e., an intersection process). It can potentially benefit
real-world applications in the case where labeling data is difficult or (more likely) it is expensive to
obtain sufficient marked samples. Also, during the selection of data samples with active learning, the
accuracy is superior to a traditional supervised learning scheme. For example, a recent study [98] has
explored an active learning scheme with an SVM classifier for the brain tumor segmentation task.
• Ensemble Learning [99] combines different weak classifiers to produce a stronger classifier for classi-
fication, which is in contrast to learning a single function as in the classic supervised learning setting.
It is known that, ensembles of weak classifiers tend to empirically yield better results, especially
when there is significant diversity among different models [100]. For example, due to the heterogene-
ity of brain tumor data, by ensemble learning, multi-view modeling (e.g., learning from different MRI
modalities) may be used to boost final outputs for tumor response analysis. However, a limitation with
ensembles is that it is difficult to explain why decisions are made, so they provide minimal clinical
insights.
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CHAPTER 3
MULTI-SCALE LOCAL COMPUTATIONAL FEATURE EXTRACTION
3.1 Note to the Reader
Part of this chapter was published the proceedings of the 2013 IEEE International Conference on Sys-
tems, Man, and Cybernetics [101]. Permission is included in Appendix A.
3.2 Introduction
Automated prediction of patient-specific disease progression has the potential to significantly contribute
to clinical treatment. In this chapter, we present a multi-scale local computational feature extraction method
to tackle the image-guided survival time prediction problem. Inspired by the assumption that “niche” tumor
regions may play a significant role in cancer diagnosis, we explore visual local variations from multiple
MRI sequences. The research consists of three parts (Figure 3.1): 1) the extraction of multi-scale Local
Binary Patterns (LBP) to describe the visual variations; 2) a supervised forward feature selection approach,
a Feature Ranking Model (FRM) which captures single feature predictive ability efficiently, and combines
good features to form a feature subset; 3) We cast the clinical survival time prediction task as a binary
category classification problem. We tested the framework using a dataset of 32 cases collected from The
Cancer Genome Atlas (TCGA). We obtained a 93.75% accuracy rate for the prediction of survival time.
Brain tumors are heterogeneous through a wide range of temporal and spatial scales [1]. They exhibit
significant regional differences in contrast enhancement along with variations in cellular density, water con-
tent, fibrosis and necrosis. In clinical practice, this heterogeneity is typically described in non-quantitative
terms; the lack of quantifiable metrics limits a further accurate diagnosis. We study automated survival time
prediction of patients with Glioblastoma Multiforme (GBM), which is a primary brain tumor with a poor
prognosis. GBMs are universally fatal: although current therapies can prolong survival, but they fail to fully
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eradicate or even control the GBM tumors. Little work has been proposed using texture feature analysis
with brain tumors. More specifically, no prior work deals with local visual variation in brain tumor analysis.
Multiple Local 
Scale Feature 
Extraction
Feature 
Ranking Model
Automated
Prediction
Figure 3.1: The proposed framework.
We analyze visual texture patterns within the tumor. Texture features have been widely studied in the
computer vision and pattern recognition area within various applications [9][10]. Essentially, image texture
is defined as a description of the spatial variation in pixel intensities and such sets of local statistics are con-
stant, slowly varying, or approximately periodic [11]. For oncology, these local statistics may be meaningful
due to the fact latent niche areas may play a crucial role in cancer disease diagnosis. Hence, we are inter-
ested in leveraging the variations in niches by observing the local neighborhood features using Local Binary
Patterns (LBP) [12]. We have used the multi-scale local texture descriptors of LBP to explore the underly-
ing implication from MRI. Since the heterogeneity of radiographic characteristics in cross-sectional clinical
imaging is well recognized, we used three MRI sequences (post contrast T1-weighted, FLAIR, T2-weighted)
for our study. Once the region of interest (tumor here) is identified, the multi-scale LBP descriptors were
used to extract meaningful local features. Additionally, we used clinical survival time attributes in our study.
Based on the clinical statistics, the GBM dataset was empirically divided into two categories: Short Term
and Long Term cases. Hence, we consider clinical survival time analysis as a supervised binary classification
problem (Figure 3.2).
In addition, we propose a simple yet effective feature ranking model to select a meaningful feature
subset. The basic idea is to efficiently capture the predictive power of a single texture feature by observing
its nearest neighbor examples in feature space, and to concatenate them together to represent the intrinsic
visual structure of a tumor. In fact, searching for the optimal feature set often confronts one with exhaustive
(or more likely) greedy search: once a single feature is selected, it leads to the stage of searching for the best
two single features in an incremental learning scheme, and so forth. A positive for our proposed approach
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is that the only criterion for feature selection is to examine a single feature independently, thus it does not
suffer of the extra computational cost from combining subset features greedily.
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Figure 3.2: Clinical survival group prediction.
3.3 Multi-scale Feature Extraction
Given a tumor region, the operator takes a local neighborhood around a specific central pixel (gc). By
setting a threshold, its neighborhood pixels within a circular radius of R (gp with p=0,1,2..p-1) are converted
into 0s and 1s. Finally, a binary number representation of gc is created. Figure 3.8 illustrates the LBP op-
erator for a pixel computation within the tumor. This computation repeats for each pixel in a given region.
We follow [42] using the same notation (P,R), which describes a pixel neighborhood structure. It depicts a
pairwise relationship: P sampling points are on a circle of radius of R. Thus, the central pixel is represented
by the obtained binary number. A compact binary code is obtained for the entire tumor. Formally, the LBP
(P,R) is given below:
p−1∑
p=0
s(gp − gc)2p, where s(x) =
 0 for x < 01 for x ≥ 0 (3.1)
All descriptors are computed in terms of powers of two and summed into decimal values. In our experi-
ments, a coherent LBP histogram was concatenated for feature representation (Figure 3.4). This histogram
statistically characterizes each primitive (niche region). To fully capture statistical local variations, we used
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(P,R) = {(4,1),(8,1),(8,2),(8,3) and (16,2)} in our study. It is expected that these multi-scale neighborhood
features vary across modalities of MR sequences.
Figure 3.3: LBP feature extraction.
3.4 Supervised Feature Selection
Extracting features from images can result in hundreds or thousands dimensions. For instance, consider
the extracted texture features here: we have 256 (28) dimensions or histogram entries for LBP (8,1) and
655356 (216) dimensions for LBP (16,2). Redundant (or irrelevant) features will lead a classifier to create
spurious models for small amounts of training data (such as here). As a result, to increase efficiency and
accuracy in learning tasks, efficient feature selection is imperative since it reduces the number of features
while preserving the intrinsic patterns maximally [52] [57] [65]. One way of dividing feature selection
methods is to consider feature subset selection methods and individual feature ranking methods. First,
feature subset selection methods usually involve more computation and require a suboptimal search of the
possible feature combinations. For example, wrapper-based feature selection views the selection in terms
of a classification problem involving the classifier in a feature subsets search. Second, individual feature
ranking methods focus on single feature performance sequentially.
We propose a type of supervised forward feature selection algorithm—the Feature Ranking Model
(FRM). The basic idea follows the strategy of individual feature ranking to select individual features ac-
cording to their predictive likelihood. Due to a relatively small medical data set (32 cases) we tested each
feature independently using a leave-one-out cross validation. This means all training data is used to select
features making our results an upper bound on accuracy for a given classifier. Usually, a specific feature
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selection approach works well under some assumptions about the data distribution. Our approach here uti-
lizes the measurement of the mean value of the feature for each class. We use a simple nearest neighbor
criterion to test each feature. Given N training samples D ={xn, yn}Nn=1, where each sample xn consists of
M features and yn ∈{-1,1} is a class label. At each round, we select a single feature fi ∈ RN , 1 ≤ i ≤ M .
Suppose we choose xt,i as the test example, the rest of the examples (xr,i, r 6= t) are used for training and
all have just feature fi. We compute m1 and m2, defined as the mean feature values of the two classes
from training examples. The test example is compared to the mean of each class and gets a score (st = 1
or -1) based on which class mean it is closest to. Hence, an accuracy pi of the selected single feature fi
is computed by comparing the obtained score with ground truth label yn. This process is repeated until all
features are tested. Finally, the top features are selected according to their accuracies. This is conceptually
similar to the one Nearest Neighbor (1-NN) rule: we use the mean value of the examples in each class in the
test set which will be potentially stable. The binary class problem can be extended to multi-class problems
as well. A formal description is given in the Algorithm 1.
Algorithm 1: Feature Ranking Model
1: Input: let D = {xn, yn}Nn=1, where xn consists of M features xn,i (i=1,2..,M), and class label yn
∈{-1,1}
2: for all i=1: M do
3: Set pi = 0
4: for all t = 1: N do
5: Set st = 0
6: Testing example: Ttest = xt,i, the ith feature of xt.
7: Training examples: Ttrain = {xr,i|r 6= t, r ∈ [1, N ]}
8: Compute m1 = mean(Ttrain ,where yr = 1 )
9: Compute m2 = mean(Ttrain ,where yr = −1)
10: if |Ttest - m1| ≤ |Ttest - m2| then
11: Set st = 1
12: else
13: Set st = −1
14: end if
15: end for
16: Compute the accuracy pi by comparing
17: s = [s1, s2, .., sn] with the label [y1, y2, .., yn].
18: end for
19: Output: top features with pi in decreasing order
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As a side note, we are testing the predictive power of a single feature in terms of accuracy. However,
other criteria can be used as well, such as false positive, false negative rate, etc. In this method, since it is
a single feature ranking model, it does not account for feature correlations. The ranking algorithm above
summarizes the complete feature selection procedure. We demonstrate good empirical success using the
proposed feature selection method for prediction in experiments.
3.5 Multi-modality MRI Dataset
A dataset of 32 patients (594 total slices) with Glioblastoma multiforme (GBM) brain tumors was col-
lected from the cancer genome atlas (TCGA) [88]. All patient identifiers were removed. The dataset in-
cluded multiple MRI slices in the axial plane: post-contrast T1-weighted, FLAIR and T2-weighted modali-
ties. T1-weighted images measure the blood flow in brain tumors. T2-weighted and FLAIR images charac-
terize interstitial edema. The inclusion of a study in the dataset mainly relies on two factors: multi-modality
scans and available clinical survival time. First, we selected cases that had the needed multi-modality scans
available. Second, selected cases should have available survival time information. From the TCGA, we
found that long term survival cases are less available than short term survival cases, and the multi-modality
requirement reduces the available amount of data.
The survival time of each patient was defined as the number of days between the date of the initial
pathological diagnosis and the time of death. Since there is no explicit prior work on the precise definition
of the survival time criterion, we choose to approximately follow the previous work [47], where the median
survival time length is 12-15 months. Using this median criterion, the dataset was divided into two cate-
gories: Group1 (16 cases, survival < 400 days) and Group2 (16 cases, survival ≥ 400 days), respectively.
In this way, we were able to assign a group label to each case. Note that there may multiple sub-groups
in the survival population, the major reasons for choosing this binary classification scheme were: 1) to en-
sure sufficient training samples of the predictive model; 2) two distinct groups reflect underlying extreme
survival groups that present significant clinical interests. To obtain reliable performance, the ground truth
tumor boundary was manually identified with help from a radiologist. Table 3.1 summarizes the dataset
information.
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Table 3.1: Dataset summary
Attributes Description
Modality T1-weighted, FLAIR, and T2-weighted
Slice thickness 3-5mm
Total slices 594
Slice size in pixel 256 × 256
Survival group1 145 ± 109 (days)
Survival group2 846 ± 448 (days)
Our goal is to automatically predict a survival type based on the initial diagnostic scan of a patient. A
Support Vector Machines (SVMs) classifier [102] was employed using the selected features. Our contribu-
tions are two-fold: first, to the best of our knowledge, it is the first effort to quantitatively investigate survival
time prediction of GBM patients with local visual variations from MR images. This may be viewed as a
perspective related to tumor heterogeneity analysis; second, we propose a ranking based feature selection
approach to efficiently select the optimal texture feature set for the computer-assisted prediction task. The
results show that it is superior to the state-of-the-art feature selection methods.
(c) LBP descriptor(a) Tumor slice (b) Tumor region
Figure 3.4: LBP feature visualization.
3.6 Feature Ranking Performance
In this subsection, we evaluate our feature selection algorithm. As discussed in the previous section, five
LBP features at different scales were applied for testing. We tested the proposed method on the 3 different
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modalities respectively (T1-weighted, FLAIR, T2-weighted). For each modality, the texture descriptors
were computed on each slice with tumor presence. The volumetric feature representation was formed by
concatenating features from the three modalities of each slice.
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Figure 3.5: Ranking performance on T1-weighted data.
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Figure 3.6: Ranking performance on FLAIR data.
Figures 3.5, 3.6, 3.7 show plots of overall performance on the sorted features. Each figure demonstrates
the accuracy of single feature on a particular modality with respect to its feature index. Particularly, we
sorted each single feature in decreasing order with regard to its accuracy. It is notable that all three figures
show similar curves. For instance, looking at the LBP(4,1), we have a total of 16 features. LBP(4,1)
falls sharply due to the small number of dimensions (16 only). Likewise, it only considers 4 orthogonal
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Figure 3.7: Ranking performance on T2-weighted data.
neighborhoods. This simple structure limits its performance compared with others. When we turn to other
descriptors, we find that all three 8 neighborhoods textures (LBP(8,1), LBP(8,2) and LBP(8,3)) have poor
performance as we approach 256 features. Also, no descriptor is definitely superior to the others in the
feature set. Meanwhile, all three descriptors achieve relatively stable performance with their highest test rate
(in a range [0.65, 0.75]) on all three modalities. It is noted that, due to the limited space for plotting, we only
delineate the first 300 dimensions, which cover all the descriptors, except the LBP(16,2). Since LBP(16,2)
uses a more complex neighborhood structure than others, it may have better results. We observe that, the
most striking result was seen for LBP(16,2). It allowed for the highest accuracy of 0.85 to be obtained on
the T2-weighted data. Moreover, its performance was consistently better than the other descriptors. There is
a trade-off as it requires the longest time to compute. In order to obtain better prediction results, we selected
a subset of these LBP features for our prediction task in a later section. We follow the rule that any single
feature with an accuracy above a given percentage will be selected.
3.7 Prediction and Comparison Results
In our work, we used the libSVM package [102] in experiments. We used the Radial Basis Function
(RBF) kernel. To ensure the best results, the gamma and cost parameter C were tuned by the cross validation.
All features are scaled into the range [-1,1]. We evaluated the prediction results by comparing the predicted
label of each data sample with each ground truth label. A leave-one-subject-out cross validation scheme was
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adopted. After testing on the dataset, we are able to obtain the true positives (TP), true negatives (TN), false
positives (FP), and false negatives (FN) for each class. We used the mean accuracy to measure the overall
performance. In addition, we incorporated two popular feature selection methods for comparison. Thus, the
following three feature selection algorithms are compared:
• The Proposed Feature Ranking Model (FRM).
• Relief-F [62]: It is a filter-based feature selection approach by estimating the quality of features
according to how well their values distinguish between instances that are near each other.
• t-test [61]: namely, the student t-test. It can be used as a test statistic to assess the significance of a
feature.
Different numbers of feature subsets were chosen for testing. In our feature selection method, after
setting a threshold accuracy, any single feature with accuracy above this value will be included in a feature
subset. To have a thorough evaluation, we expect to select different subsets, we empirically picked 5 different
accuracy values (0.8, 0.75, 0.72, 0.7, and 0.65 ) to obtain the subsets. Accordingly, we got 5 feature sets
with N = (9, 27, 98, 267, and 741) dimensions, respectively. It is noted that if we change the accuracy
threshold slightly, this number of selected features does not change (i.e., if we set 0.65 to 0.66). A potential
limitation of FRM is the indirect control of the number N of selected features, as it is possible that we have a
number of features with the same accuracy rate. In this situation, a sampling strategy could further be used
to alleviate the problem. For fair comparisons, the selection of N for each subset is kept the same across all
these three methods.
On our dataset, without any learning scheme, a baseline of prediction rate is 0.5 by guessing the majority
class. As seen from Table 3.2, two types of SVM solvers (SMO-SVM and nu-SVM) were used. The first
type is based on the sequential minimal optimization (SMO) to solve the quadratic programming problem
involved in implementing an SVM; The second type is based on setting a parameter “nu”which controls
the number of support vectors (default nu = 0.5). We sorted each subset with respect to its dimensions
in ascending order. Overall, the proposed model obtains competitive results and the highest accuracy is
93.75% obtained from using subset 2 (27 features total). Relief-F (the size of the neighborhood is 5) exhibits
relatively weak results for this data. The results of t-test are close to FRM possibly because it similarly
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Table 3.2: Prediction results
Approach Subset1 Subset2 Subset3 Subset4 Subset5
FRM with SMO-SVM 90.63% 93.75% 84.38% 87.50% 90.63%
FRM with nu-SVM 90.63% 90.63% 87.50% 84.38% 78.13%
T-test with SMO-SVM 84.38% 90.63% 87.50% 87.50% 84.38%
T-test with nu-SVM 90.63% 90.63% 87.50% 90.63% 87.50%
ReliefF with SMO-SVM 71.88% 75.00% 75.00% 71.88% 75.00%
ReliefF with nu-SVM 65.63% 75.00% 75.00% 75.00% 71.88%
Table 3.3: Statistical significance evaluation
Comparison Classifier Subset1 Subset2 Subset3 Subset4 Subset5
FRM and T-test SOM-SVM 0.68 0.47 1 1 0.48
FRM and ReliefF SOM-SVM 0.27 0.11 0.18 0.04 0.04
FRM and T-test nu-SVM 1 0.62 0.62 1 0.02
FRM and ReliefF nu-SVM 0.04 0.002 0.45 0.29 0.72
measures the data samples via the mean, variance distributions. Additionally, to test if any difference is
statistically significant between two feature selection approaches, we used McNemar’s test [103] to compare
the pair of predicted labels for two chosen approaches. Table 3.3 shows the two-tailed P values for different
feature subsets, indicating that no statistical significance is given between FRM and the T-test; between
FRM and ReliefF, statistical significance is observed for 4 feature subsets.
Furthermore, we conducted a cross validation to compare these feature selection approaches. With a
leave-one-out cross validation, different number of feature subsets (top 10 to 100 features) were selected
from each training fold. The SMO-SVM classifier was used for predicting test samples with the selected
features. As seen in Figure 3.8, the proposed method allowed for higher accuracy results than competing
methods for all selected feature sets. Although the highest result of 90.63% is slightly lower than the best
one from Table 3.2, the proposed method results in higher accuracy than competing methods for all feature
sets in cross validation.
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Figure 3.8: Fold-wise feature selection performance.
Table 3.4: Modality contribution
Modality Subset1 Subset2 Subset3 Subset4 Subset5
T1-weighted 56% 48% 48% 43% 39%
FLAIR 11% 15% 27% 27% 28%
T2-weighted 33% 37% 25% 30% 33%
3.8 Modality Contribution
In addition to the prediction, we further investigated the contribution of the texture features for the
survival time prediction task. In other words, for each feature subset, we recorded the texture features from
each modality: T1-weighted, FLAIR, and T2-weighted that were selected. Table 3.4 presents a detailed
distribution of the contributions of these five feature subsets. For instance, feature subset 1 consisted of 56%
T1-weighted, 11% FLAIR, and 33% T2-weighted data. We observed that, among all five sets, T1-weighted
texture features make a significantly greater contribution than the other two modalities. This indicates
that T1-weighted data may contain rich informative patterns. If we compare Table 3.4 with the prediction
performance in Table 3.2 (the best prediction rate is from subset 2), it uncovers a potential property that: 1)
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the use of T1-weighted data is not sufficient; 2) better performance could be achieved by a combination of
these three modalities.
3.9 Remarks
In this chapter, we investigated the relationship between statistical local visual variations and the het-
erogeneity of brain tumor diagnosis. Automated patient-specific diagnosis is an active area and could play a
crucial role in the development of therapies for cancer. An efficient feature ranking model was proposed for
the specific task of automated survival time prediction for patients with GBM. Particularly, we have found
that: 1) local visual features can be used to obtain accurate survival time prediction with GBM patients;
2) T1-weighted MR sequences make the most contribution to the survival time prediction problem. In a
nutshell, this work provides a more in-depth understanding that tumor heterogeneity exists and matters. In
the future, we are interested in exploring more advanced machine learning techniques for this prediction
problem.
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CHAPTER 4
SPATIALLY-EXPLICIT QUANTIFICATION OF BRAIN TUMOR MRI
4.1 Note to the Reader
Part of this chapter was published in the proceedings of the 2014 IEEE International Conference on
Pattern Recognition [104]. Permission is included in Appendix A.
4.2 Introduction
In this chapter, we focus on a quantitative exploration of intratumor variations. In clinical MRI imaging,
radiological heterogeneity is well recognized: brain tumors of the same type, but in different patients, can
have remarkably diverse visual appearances. In medicine, typical expressions—“necrotic”, “enhancing”,
and “edematous”—are commonly used to describe imaging characteristics of tumors. However, these qual-
ities often vary throughout the tumor volume and can change over time. Thus, most of these descriptions
are subjective, lacking a quantitative measurement. Furthermore, these descriptors can vary spatially within
a tumor which restrains their contribution to cancer therapy. For example, describing a GBM as ”necrotic”
does not really mean that the entire tumor is necrotic—only a certain fraction of it is. But, of course, other
regions of the tumor are well vascularized. Thus, a more accurate description of the tumor would be some-
thing like the tumor is generally heterogeneous, because it contains multiple regions with different imaging
properties, but each of these sub-regions may (or may not) be homogeneous. As a result, we propose there is
a limitation in understanding the clinical dynamics of GBM based on sequential MRI scans: current features
are typically without “spatial information”, and explicit identification of multiple distinct tumor sub-regions
which would facilitate observation and characterization of tumor evolution before and during therapy.
To better understand this issue, we investigated tumor heterogeneity by introducing the concept of “tu-
mor habitats” (as suggested by Gatenby in [10]) as prognostic biomarkers, which describe spatially homo-
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geneous (or distinct) regions of brain tumors. We built the proposed model based on the idea that observable
regional variations are essential to fully describe tumor heterogeneity. Our goal is to develop an approach
that automatically identifies specific sub-regions of the tumor to provide insights into the underlying tumor
evolutionary dynamics. We present a joint mapping of different MRI sequences which yields predictive
information for clinical outcomes of patients with GBMs (as illustrated in Figure 4.1). In particular, the
heterogeneity can be captured via two main steps: 1) tumor sub-regions obtained from the intratumor seg-
mentation approach; 2) a spatial mapping scheme from a multi-modality MRI imaging dataset (T1-weighted,
FLAIR and T2-weighted MRI slices). A tumor region is initially segmented into high and low signal groups
and then a joint mapping scheme is used to consider the correlation between different input modalities. In
addition, focusing on the contrast within these groups, we propose a set of quantitative features to measure
differences between sub-regions.
We examined the predictive capability of regional habitats by predicting the clinical survival time in
a cohort of 32 patients with malignant GBMs enrolled in The Cancer Genome Atlas (TCGA) database.
Analyzing survival time can help the understanding of potential risk factors, and further enable patient-
specific therapies. In our study, unlike survival time analysis, which uses a regression-based computation
to estimate the survival time of individual patients, we cast the survival time prediction problem as a binary
group classification task, which tends to reflect distinct group survival characteristics. Based on the clinical
survival time distribution, the dataset was empirically divided into two typical categories (i.e., short and long
term groups). Experiments showed that the proposed quantitative features based on the differences between
these habitats were effective for the clinical survival group prediction task.
4.3 Framework
In this section, we introduce our approach to explore brain tumor heterogeneity via multi-modality
MRI. It begins with the regional area quantification—habitats definition. Second, we examine the features
extracted from tumor habitats. Third, we built classifiers for the survival group prediction task.
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Figure 4.1: Illustration of the proposed framework. (a) A pair of MRI slices with tumor were selected as
inputs. (b) Each modality was segmented by Otsu segmentation. The tumor region was separated into high
and low sub-regions (in terms of voxel intensity) for the two modalities respectively. (c) Spatial mapping
imposes an overlap between segmented modalities. Then, contrast sub-regions were defined as high and
low signal groups. (d) Features extracted from contrast regions are given to a machine learning algorithm to
build a classifier for clinical survival group prediction.
4.3.1 Habitats Definition
A challenge of quantifying intratumor variations is the heterogeneity of cancer data. It is particularly
difficult to define optimal intratumor regions for computational modeling. To make a step towards un-
derstanding regional variation, our approach relies on brain tumor anatomy—brain tumor structure can be
typically represented as its active cells and necrosis. In particular, the defined tumor habitats used to capture
local tumor variations are created in two steps: intratumor segmentation and spatial mapping. To do so, we
begin with an automated segmentation technique to yield semantically meaningful tumor regions.
4.3.2 Intratumor Segmentation
We propose a binary segmentation to define the sub-regions. For each modality, two intratumor habitats
(in terms of high and low MRI signals) were obtained using the non-parametric Otsu algorithm [105]. It
iteratively searches for an optimal decision boundary to ultimately partition the tumor region into high and
low signal groups. Figure 4.2 illustrates the intratumor segmentation by applying Otsu on the T1-weighted
modality. Because we consider a segmentation using one MRI modality, it is suitable to apply Otsu (more
details can be found in [105]). Once intratumor regions were generated from a particular modality, a similar
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process was conducted on the other modalities as well. Thus, after obtaining two regional groups from each
modality, we explored the correlation among them using a spatial mapping scheme. Although it remains an
open issue to achieve the optimal number of sub-regions, it is intuitive to follow the binary partition, which
is built on a fundamental tumor semantic understanding that contrast signals between specific tumor regions
(i.e., active cells and necrosis) can well define major tumor components.
4.3.3 Spatial Mapping
Multi-modality MRI presents various underlying tumor characteristics. To fully utilize the MRI variabil-
ity, we propose a fusion-based analysis—spatial mapping—to explicitly quantify distinct tumor sub-regions.
Spatial mapping was done via an intersection operation between the habitats obtained from two different
modalities. As shown in Figure 4.3, two segmented boundaries were mapped onto each other to further split
the area into different sub-regions. To seek a contrast between blood flow and cellular density, we defined
two sub-regions with emphasis on the signal (intensity) contrast (i.e., when both segmented regions had high
signals and both had low signals): High Signal Group (HSG) and Low Signal Group (LSG). For example,
considering the spatial mapping between the T1-weighted and FLAIR modalities: HSG was a group where
both High T1 and High FLAIR signals were observed, and LSG was a group where both Low T1 and Low
FLAIR signals were present. Notably, we do not consider mixed signal groups due to the fact that they
may not reflect useful tumor biological characteristics for clinical interpretation. After spatial mapping, we
were able to quantitatively observe tumor heterogeneity in terms of MRI signal contrast. In Figure 4.3,
colored output from the spatial mapping process is shown: the red and blue areas are the HSG and LSG for
a particular case.
The distinctive habitats describe spatially explicit regional characteristics. The process of joint con-
sideration of different modalities is based on the fact that different modalities capture various underlying
characteristics of cellular dynamics. The novelty of the proposed habitats is to quantify sub-regions ex-
plicitly using multi-modality MRI, unlike previous studies that mostly focused on single modality analysis.
Conceptually, the spatial mapping analysis provides a way to observe local regional variations of the tumor.
The distinct tumor sub-regions hold the potential to be linked to genetic mutation analysis. The visual char-
acteristics can be ascribed to genetic or chromosomal rearrangement which in turn will affect prognosis and
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response to therapy [10]. In fact, the proposed method is in line with the emerging science of radiomics [36],
which aims at using a high-throughput technique to extract a large number of quantitative attributes for can-
cer analysis. Furthermore, we make a step towards a more in-depth quantification by using regional and
contrast variations as discussed in the next section.
T1-weighted slice Segmented output
Marked tumor region
Figure 4.2: Intratumor Otsu segmentation outputs. The tumor boundary is manually identified as shown
with the yellow line. The light grey area is the segmented high signal region and dark grey area is the
segmented low signal region.
4.3.4 Group Difference Features
To examine the predictive capability of tumor habitats, we proposed a set of Group Difference Features
(GDFs) to quantify habitat variations. Following the prior discussion, to obtain the sub-regions via spatial
mapping, we considered all pairs: T1-weighted and FLAIR; T1-weighted and T2-weighted; and FLAIR and
T2-weighted. For each pair, we were able to create groups: HSG and LSG. Features were then extracted
only from these sub-regions. Instead of a raw voxel representation which is noisy and sensitive to outliers,
we used image descriptors to extract meaningful patterns from each habitat. In our study, we used Local
Binary Patterns (LBP) [42] as the feature descriptor, as they have been widely shown to be a robust type of
local texture feature. More details can be found in the previous Section. Following [42], we used (P,R) to
denote the local neighborhood structure, where P samplings lie on a circle of radius R.
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To compute the statistical local variations and fully quantify the tumor heterogeneity, we consider a
multi-scale LBP feature extraction process. Five multi-scalars are considered (P,R)(k) ∈ {(4,1), (8,1), (8,2),
(8,3), (16,2)}, k ∈ [1,5] in our study. Correspondingly, given a scalar (P,R)(k), two sub-regions (HSG and
LSG) T (k)H and T
(k)
L were used to extract LBP histograms. We then explored the difference between these
signal groups. For each case, we defined the vector difference between HSG and LSG:
GDF(HSG,LSG)(k) = |T (k)H − T (k)L |, k ∈ [1, 5] (4.1)
It is noted that GDF(HSG,LSG) was used to explore how features varied with respect to the distribution
of contrast signals (HSG and LSG) for each case. A pair of modalities enable us to obtain a pair of feature
sets since the obtained habitats (HSG and LSG) were directly projected back onto each modality (as shown
in Figure 4.3). Then, from each modality, local computational features were extracted separately. Thus,
based on a pair of input modalities, two histogram features were obtained. GDF measures the contrast infor-
mation between different signal groups, and it further quantifies brain tumor heterogeneity. After obtaining
various feature sets, we proposed a supervised feature selection approach to select predictive features from
each extracted GDF feature vector. The top predictive feature vectors were selected separately and then
concatenated into a selected feature vector for the prediction task.
4.3.5 Survival Group Prediction
Once the selected feature set is chosen, to efficiently evaluate the prediction power of the obtained
features, we used three classifiers including K-nearest neighbors (KNN) [106], Naive Bayes (NB) [107],
and Support Vector Machines (SVM) [102].
Given a labeled dataset {X,Y } = {(~x1, y1), (~x2, y2), ..., (~xn, yn)}, where each sample is ~xi ∈ Rm
and yi ∈ {c1, c2} is the class label. KNN is an instance-based classifier that searches nearest neighbors
in the instance space and predicts the unknown test sample by a majority vote. For a test sample x, the
KNN decision rule applies to find the majority class label of the k nearest neighbors. In this study, we
used the Euclidean distance to measure the distance between feature samples and used k = 1 to search
for the nearest neighbor. The Naive Bayes classifier is based on Bayes theorem with a naive assumption
on the independence of each feature, its results often provide a baseline accuracy for the test data. SVM
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can efficiently tackle high dimensional data classification well. In particular, the use of a kernel function
projects data into a higher dimensional space. The optimal decision boundary is made by a hyperplane,
which finds the maximal margin between two classes. The parameters of the SVM were chosen by a grid
search. We used the LibSVM with Sequential minimal optimization (SMO). The kernel function used in our
SVM classifier was the Gaussian radial basis function kernel, where xi and xj were defined as two feature
vectors, σ was the radius parameter which controls the scale of the Gaussian kernel.
K(xi, xj) = exp(−||xi − xj ||
2
2σ2
) (4.2)
4.4 Experiments
In this section, we evaluate the proposed approach by testing its ability to do survival group prediction
where different extracted feature sets from tumor sub-regions are considered. In particular, we first examined
the regional features’ performance by single feature accuracy. We then show how combining various feature
sets improved the prediction performance. Third, we conducted a survival time analysis to observe the
estimated survival distributions using Kaplan Meyer curves.
4.4.1 Evaluation Metrics
In this study, we used a dataset of 32 brain tumor patients, and arbitrarily defined Group2 (long term
cases surviving over 400 days) as the positive class (Pc) and Group1 (short term cases surviving less than
400 days) as the negative class (Nc). Given a binary class, the confusion matrix consists of True Positives
(TP), False Positives (FP), False Negatives (FN) and True Negatives (TN). Then, the performance of survival
group prediction was measured by accuracy, sensitivity, and precision:
Accuracy =
TP+TN
(Pc + Nc)
(4.3)
Sensitivity =
TP
(TP + FN)
(4.4)
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Precision =
TP
(TP + FP)
(4.5)
4.4.2 Regional Features Performance
We evaluated our approach using predictive accuracy with different feature sets. We first examined
classifier accuracy of selected regional features. Second, we show classifier accuracy when combining
various feature sets to improve prediction results.
4.4.2.1 Single Feature Accuracy
Based on different local structures (P,R), we obtained GDF feature sets. For each feature set, we applied
the proposed feature selection approach to examine single feature performance. As the feature selection
algorithm showed, at the training stage, a leave-one-out cross validation was used to find the most predictive
feature; at the test stage, we computed the accuracy of the selected feature on the testing sample. Table
4.1 summarizes prediction results from the selected single feature from each mapping process. A feature
from (P,R) = (8,1) gave the best overall results. It was also noted that the mapping between FLAIR and
T2-weighted outperforms other pairs with the highest accuracy of 81.25% for a single feature. To further
evaluate feature performance with regard to different tumor boundaries, we modified manually-drawn masks
with morphological operators to obtain eroded and dilated masks (as shown in Figure 4.4). For both opera-
tions, we used a disk-shaped structuring element with a radius of 3 neighbor pixels to erode or dilate precise
identified tumor masks. Results from Tables 4.1, 4.2, and 4.3 suggested that morphological operations on
precise tumor boundaries lead to decreased performance and precise delineation of tumor areas is significant
for habitats analysis. Specifically, results using the eroded boundary show higher accuracies than results us-
ing the dilated boundary, which is probably due to the fact that inclusion of external brain tissues makes the
analysis more challenging.
4.4.2.2 Combined Features Performance
We evaluated combining different features obtained to improve the prediction performance on precise
identified tumor boundaries. More concretely, we defined a threshold T within [0,1] to obtain different
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feature sets for the prediction task: features that yielded a training accuracy greater than T were selected
into the combined feature set. We empirically chose different values of T ={0, 0.5, 0.7 and 0.75} for testing.
For example, if we set T>0, then all features will be concatenated into a feature vector for prediction. All
feature sets were tested using the SVM with a Gaussian kernel, the naive Bayes classifier, and the KNN
(n=1) classifier. Accuracy, sensitivity, and precision are reported for all three classifiers.
From Figure 4.5, it can be observed that for different settings of T all classifiers gave an accuracy above
80%, except the results from the naive Bayes classifier with T>0 and T>0.5. The best prediction result
of 87.5% was obtained based on 6 predictive features with T>0.75 (3 features were from the mapping
between FLAIR and T2-weighted and 3 features were from the mapping between T1-weighted and T2-
weighted, respectively). In particular, the mapping between FLAIR and T2-weighted gives the highest
accuracy of 81.25% from both training and testing folds, giving strong prognostic evidence that sub-regional
edema was predictive. Overall, we found that quantitative features from regional habitats were effective
in differentiating survival groups. From Table 4.1, it is obvious that habitats found in T1-weighted and
FLAIR, and in FLAIR and T2-weighted made a contribution to the predictive performance. Figure 4.6 shows
correctly predicted scans for both groups. Additionally, we also compared results with a recent study [108],
which used the same TCGA dataset for the survival group prediction. However, they considered a holistic
histogram analysis where the best accuracy was 80.25%, in contrast to our spatial region exploration.
4.4.3 Survival Time Analysis
We show the corresponding Kaplan-Meier (KM) curves for predicted cases. Particularly, once we had
categorical prediction labels, we were able to find associated survival lengths for these patients and link them
to the survival time analysis. Figure 4.7 illustrates the KM curves for two survival groups of the dataset.
Clearly, a better estimate is obtained when predicted curves fit close to the corresponding true curves (the
green curve indicates the ground truth distribution; the three remaining curves show predicted curves from
different classifiers). Here, we choose to plot the graph based on the highest accuracy from each classifier.
From visual inspection, group 2 (long term class) showed a better estimation than the group1 (short term
class). All survival curves between two groups were significantly different by a t-test (P-values were 0.06%,
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0.01%, and 0.05% for SVM, NB, and KNN predictions respectively) and lead to a rejection of the null
hypothesis at the 5% significance level for NB and KNN classifiers.
4.5 Remarks
Defining and quantifying brain tumor spatial heterogeneity via clinical MRI is an emerging topic for
image-aided therapy and could be beneficial to the long-term goal of successful treatments for brain cancers.
The proposed work describes a novel framework to quantitatively extract imaging features of brain cancers.
We analyzed brain tumor heterogeneity using an application of survival group prediction, and achieved the
prediction result of 87.50%.
Our method quantitatively examined spatial heterogeneity in GBMs and thus, has the potential to fol-
low the evolution of each region over time in response to therapy. Unlike traditional feature extraction on
the entire tumor, in which the “spatial quantification” was largely neglected, we proposed a spatial con-
trast analysis to explore intratumor heterogeneity. Indeed, regional variations could reflect different scales
of molecular or tissue-level dynamics, and such imaging characteristics provide a potential path for un-
derstanding the underlying biological evolution. Thus, it will be particularly promising to link observable
regional tumor characteristics and associated genetic factors.
The potential clinical impact of the proposed work includes development of analytic tools to support
clinical decisions in patient-specific GBM treatment. Spatial mapping characterizes the explicit regional
phenotype, which provides a visible tool to provide predictive information prior to therapy and perhaps
timely assessment of regional variations of tumor response and resistance during treatment. Through such
information, treatments can be planned, assessed, or adjusted in indivdual patients throughout the course
of their disease in the context of appropriate computational models. In the future, we will investigate more
distinctive features for the survival prediction task, and we will analyze molecular, cellular, and tissue prop-
erties associated with the proposed MRI tumor habitats.
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T1-weighted T2-weighted FLAIR 
(a) A case from survival group1
T1-weighted T2-weighted FLAIR 
(b) A case from survival group2
Figure 4.3: Tumor habitats visualization. Red regions are for high signal from both MR1 and MR2. Blue
is region for low signal from both MR1 and MR2. The yellow region is for high MR1 and Low MR2. The
pink region is for low MR1 and High MR2.
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Table 4.1: Prediction results using precise boundary from best single feature
Structure (P,R)
Mapping between T1-
weighted and FLAIR
Mapping between
T1-weighted and T2-
weighted
Mapping between FLAIR
and T2-weighted
T1-weighted FLAIR T1-weighted T2-weighted FLAIR T2-weighted
(P,R) = (16,2) 75.00% 71.88% 56.25% 56.25% 78.13% 75.00%
(P,R) = (8,3) 75.00% 71.88% 75.00% 75.00% 78.13% 78.13%
(P,R) = (8,2) 75.00% 71.88% 75.00% 78.13% 78.13% 78.13%
(P,R) = (8,1) 78.13% 75.00% 71.88% 68.75% 81.25% 71.88%
(P,R) = (4,1) 59.38% 65.63% 65.53% 65.53% 62.50% 65.63%
Table 4.2: Prediction results using dilated boundary from best single feature
Structure (P,R)
Mapping between T1-
weighted and FLAIR
Mapping between
T1-weighted and T2-
weighted
Mapping between FLAIR
and T2-weighted
T1-weighted FLAIR T1-weighted T2-weighted FLAIR T2-weighted
(P,R) = (16,2) 56.25% 56.25% 56.25% 62.50% 62.50% 65.63%
(P,R) = (8,3) 65.63% 65.63% 71.88% 68.75% 62.50% 68.75%
(P,R) = (8,2) 62.50% 65.63% 68.75% 65.63% 62.50% 71.88%
(P,R) = (8,1) 62.50% 59.38% 62.50% 65.63% 65.63% 68.75%
(P,R) = (4,1) 62.50% 81.25% 59.38% 68.75% 68.75% 68.75%
Table 4.3: Prediction results using eroded boundary from best single feature
Structure (P,R)
Mapping between T1-
weighted and FLAIR
Mapping between
T1-weighted and T2-
weighted
Mapping between FLAIR
and T2-weighted
T1-weighted FLAIR T1-weighted T2-weighted FLAIR T2-weighted
(P,R) = (16,2) 56.25% 56.25% 62.50% 65.63% 65.63% 59.38%
(P,R) = (8,3) 59.38% 65.63% 65.63% 75.00% 62.50% 62.50%
(P,R) = (8,2) 59.38% 59.38% 62.50% 68.75% 65.63% 62.50%
(P,R) = (8,1) 56.25% 62.50% 65.63% 68.75% 68.75% 68.75%
(P,R) = (4,1) 56.25% 56.25% 62.50% 65.53% 71.88% 75.00%
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Figure 4.4: Illustration of tumor boundary identification. Yellow boundary is the precise identified shape of
the tumor. Red and green boundaries are with erosion and dilation morphological operations.
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Figure 4.5: Prediction performance from combined feature sets. SVM achieves the best accuracy and sen-
sitivity results. High precision indicates a strong accuracy in predicting the positive class (the long term
group).
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(a) Examples of correctly predicted scans from group1
(b) Examples of correctly predicted scans from group2
Figure 4.6: Examples of correctly predicted data samples. Based on visual inspection, due to intrinsic tumor
heterogeneity, we note that cases from both group1 and group2 show large variations with regard to visual
attributes such as the tumor location, appearance, shape, and volume.
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Figure 4.7: Kaplan-Meier survival curves performance. We compare the ground truth survival groups with
predicted outcomes obtained by different classifiers.
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CHAPTER 5
RADIOLOGICALLY DEFINED ECOLOGICAL DYNAMICS IN GBM
5.1 Note to the Reader
Part of this chapter was published in the Journal of Translational Oncology, 2014 [108]. Permission is
included in Appendix A.
5.2 Introduction
In this chapter, we investigate extraction information from multi-modality brain tumors by quantita-
tively assessing regional variations, and correlate these radiologically defined habitats with survival time
in patients with glioblastoma multiforme (GBM). We examined pretreatment MRI scans from 32 patients
with GBM as described in Section 3.5 for which both tumor MRIs and clinical survival records are in-
cluded. T1-post gadolinium and either T2-weighted or FLAIR images were superimposed to characterize
intratumoral habitats based on relative blood flow and interstitial edema. The patient cohort was divided
into Group1 (survival < 400 days, n=16) and Group2 (survival > 400 days, n=16). We showed that all
tumors demonstrated 5 distinct combinations of blood flow and cell density. Group1 (survival <400 days)
and group2 (survival >400 days) tumors showed distinctly different distributions in these regions. Group1
tumors contained greater volumes of habitats with low blood flow and variable cell density than long term
progressors. The proportion of tumors that showed low post-gadolinium T1-weighted signal (i.e. poor blood
flow) and relatively low interstitial edema (i.e., low signal on T2-weighted or FLAIR images) correlated to
survival groups with 81.25% accuracy. Our conclusion was that consistent combinations of blood flow and
cellular density were found in MRIs from GBMs suggesting regional variations in Darwinian dynamics.
The distribution of these radiologically defined habitats varied significantly among the different survival
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groups. Radiologically defined ecological tumor analysis may provide valuable prognostic and predictive
biomarkers in GBM due to the presence of significant cell populations reflected in phenotypes.
5.3 Background
Intra- and inter- tumoral heterogeneity is well recognized at molecular [109] [110], cellular [111] [112],
and tissue scales [113] [114]. Recent analyses have clearly demonstrated significant genetic variations be-
tween tumors in the same patient and within the same tumor [111] [112] [113]. In one study, for example,
samples from spatially separated sites within glioblastoma multiforme (GBM) tumors showed that multiple
molecular subtypes were present in all of the examined tumors [111]. This heterogeneity may significantly
limit efforts to personalize cancer treatment based on the use of molecular profiling to identify drugable
targets [115] [116] [117]. Temporal and spatial cellular heterogeneity is typically ascribed to clonal evolu-
tion governed by accumulating random mutations in cancer cell populations [118] [119]. This conceptual
model views evolution as the product of stochastic events, which implies that the molecular properties and
spatial distribution of cell populations are fundamentally unpredictable. Darwinian dynamics, by contrast,
are ultimately governed by the interactions of local environmental selection forces with cell phenotypes (not
genotypes) [120] [121]. It was found that intratumoral evolution, rather than being a chaotic process driven
by random mutations, is a predictable and reproducible dynamic system that can be understood through
evolutionary principles [121] [122]. From this observation, it is a short step to consider how clinical imag-
ing can be applied to investigate spatial and temporal variations in intratumoral Darwinian dynamics [10].
Spatial heterogeneity in tumor characteristics is well recognized in cross-sectional clinical imaging. Many
tumors exhibit significant regional differences in contrast enhancement along with variations in cellular
density, water content, fibrosis, and necrosis. In clinical practice, this heterogeneity is typically described in
non-quantitative terms. More recently, metrics [123] [124] of heterogeneity, such as Shannon entropy, have
been developed and can be correlated with tumor molecular features [36] [125] [126] [127] and clinical
outcomes [128] [129] [130]. However, metrics that assign a single value to heterogeneity tacitly assume that
the tumor is well-mixed and that every site within the tumor is equally variable. Here, our general goal is to
develop a spatially explicit approach that identifies and quantifies specific sub-regions of the tumor based on
clinical imaging metrics that may provide information about the underlying evolutionary dynamics. In this
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approach, we hypothesize that tumors will generally possess sub-regions with variable dynamics, including
environmental selection forces and phenotypic adaptation to those selection forces [10]. Our approach here
generates radiologically defined habitats by spatially superimposing two different MRI sequences from the
same tumor. Our goal in this research work is to examine regional variations in blood flow based on post
gadolinium T1-weighted, FLAIR and T2-weighted images that are sensitive to interstitial edema and likely
reflect a combination of cell density and cellular response to the environment. Clearly, a full characteriza-
tion of the Darwinian dynamics in intratumor habitats will require more extensive imaging probably from
multiple modalities (i.e. PET, MRI, and CT) or other MRI sequences (particularly ADC maps, which were
not generally available in the TCGA data set). Nevertheless, with this relatively small amount of data, we
asked the following questions: 1) Can GBMs be consistently divided into some small number of specific
radiologically defined habitats based on combinations of images sensitive to blood flow and edema? 2)
Does the distribution of these regions vary among tumors in different survival groups? This work builds on
prior studies using regional variations in MRI appearance to correlate with genetic and histological tumor
characteristics [131] including a demonstration of the technical feasibility of superimposing different MRI
sequences in clinical imaging of GBM. Here we explicitly apply a novel perspective to link clinical imaging
characteristics to intratumoral molecular heterogeneity and clinical outcomes.
5.4 Tumor MRI Data Details
All of the images had a 200mmx200mm field of view and 5mm slice thickness, with 256x256 or
512x512 in-plane resolution. For each case three channels were registered by a bilinear interpolation. Since
the enrolled patients were from multiple institutions, the studies were performed on a wide range of MRI
units with some variations in technique. We included studies only if the slice thickness was 5mm and all
MRI examinations passed a visual inspection for adequate quality prior to inclusion. Tumor boundaries
were outlined manually including both enhanced and non-enhanced regions with help from a radiologist.
Although automated tumor segmentation methods have been described, they can be unpredictably inaccu-
rate. For consistency, the regions of interest (ROI) were segmented by manually drawn masks on the post
gadolinium T1-weighted images as shown in Figure 5.1.
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(A) Axial contrast T1-wighted (B) Axial FLAIR (C) Axial T2-weighted
Figure 5.1: An example of analysis from a patient with GBM.
5.5 Approach
5.5.1 Image Normalization
To have consistent evaluations for all cases, the obtained MRI imaging data were processed by stan-
dardizing the intensity scales [132]. We employed a linear normalization on each volume. The voxels of
each volume of the tumor region were independently normalized into [0,1]. Thus, the normalization cap-
tured the local tumor variations of specific patients in the standard range. Histogram analysis: The tumor
heterogeneity analysis included 2D and 3D histogram representations.
5.5.2 Histogram Representation
A 2D histogram was used to conduct initial spatial analysis. This histogram collected the cumulative
voxel intensities of the tumor. Across different histograms, for ease of comparison, we built a histogram
with 100 bins and the frequencies were rescaled into [0,1], where higher values of a frequency indicated the
more frequent presence of that particular intensity. A 3D histogram was used to visually observe variations
in tumor heterogeneity. The x- and y- axis consisted of the available pairs of MRI modalities: T1-weighted
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and FLAIR; T1-weighted and T2-weighted; or FLAIR and T2-weighted. We used a joint histogram which
considered the cross distribution of each modality. For instance, considering the pair of post gadolinium T1-
weighted and FLAIR modalities, an aggregated histogram was formed by counting the joint intensity of each
voxel (xi,xj), where xi was denoted as the T1-weighted intensity signal and xj was the associated FLAIR
intensity signal. The z-axis dimension represented the joint distribution of each voxel. The remaining
combinations followed a similar process to obtain the 3D histogram representation.
To examine the predictive power of the histogram representation, we first proposed a set of 3D histogram
variation features. Second, a series of statistical analyses were done based on the set of features. In addition,
a clinical survival time group prediction was made to evaluate the predictability of features. Histogram vari-
ation features: for each class (c=1,2), a histogram variation feature (HVF) was computed from the following
two components: 1) the histogram template computation from a training fold; 2) the variations between the
histogram of each case and the template. In detail, histogram templates Tc (c=1,2) of each class were ob-
tained by the mean 3D histogram of all training samples from each class (as seen in Figure 5.4), where each
case was denoted as Hi (i=1 to 32). A histogram variation feature (HVF) was defined by HVF = D(Hi,Tc),
(c=1,2), where D(.) was a Chi-square distance [133] used to measure histogram vector differences. Thus,
for each case, we were able to extract two HVFs. Additionally, multi-modality data enabled three possi-
ble combinations (T1-weighted and FLAIR; T1-weighted and T2-weighted; or FLAIR and T2-weighted),
which resulted in a feature vector consisting of the 6 HVFs: D(Hi, T1)T1−FLAIR, D(Hi, T2)T1−FLAIR;
D(Hi, T1)T1−T2 , D(Hi, T2)T1−T2 ; D(Hi, T1)FLAIR−T2, D(Hi, T2)FLAIR−T2 for each case.
5.5.3 Survival Time Criterion
The clinical survival time was defined as the number of days between the date of the initial pathologic
diagnosis and time to death obtained from the patient demographics in the TCGA database. We used the
MRI imaging data which were obtained at the initial diagnosis, thus the possible influence of the following
clinical therapy was not accounted for in our study. Since there was no explicit prior study suggesting
the precise survival threshold for different survival groups, we chose to approximately follow the overall
statistics in the study [134], where a reported median value of survival time for a GBM tumor was 12-15
months. As before, the patient cohort was initially divided into two equal groups: Group1 (survival time
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< 400 days) and Group2 (survival time > 400 days), thus the criterion used here differs from that used
in another study [135], which defined long-term survival as more than 3 years (36 months); only 2-5% of
patients were in this group.
5.6 Results
5.6.1 Variations in Blood Flow and Cellular Density
Figure 5.2 demonstrates variation in the normalized values of T1-post gadolinium, T2-weighted and
FLAIR images in different survival groups. In the T1-post gadolinium images there are two populations that
are roughly Gaussian distributions around high and low means. This suggests GBMs are generally divided
into regions of high and low perfusion. Group1 demonstrates a shift in the distribution of these perfusion
regions from high to low. The T2-weighted and FLAIR distributions suggest the Group1 tumors actually
contain habitats that are either not present or rare within long term progressing tumors. For both the FLAIR
and T2-weighted histograms, the tumor volume is dominated by a single population, probably with one
other smaller population leading to some asymmetry of the Gaussian distribution. In the Group1, tumor
distribution is significantly more heterogeneous with at least 3 distinct regions.
5.6.2 Initial Spatial Analysis
Since the T1-weighted images consistently divided into two regions, we used this as a starting point
for combining sequences. All of the tumors were divided spatially into high and low perfusion regions
using a normalized intensity of 0.26 as the dividing point. The threshold was found by fitting a Gaussian
Mixture Model [136] to a cumulative histogram of all T1 post gadolinium images and finding where 2 classes
intersected. After this spatial division, FLAIR values were projected onto the high and low perfusion groups.
As shown in Figure 5.3, this resulted in clear separation of the GBM images into 5 distinct radiologically
defined combinations of blood flow and interstitial edema. In the high flow (i.e. highT1 post gadolinium)
regions, there is a region with low FLAIR signal (presumably indicating relatively high cellularity) as well
as a second habitat with high FLAIR signal where the cell density is lower and there is increased water
signal. Similarly, in the low flow (i.e. lowT1-post gadolinium regions) one sub-region shows very high
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Figure 5.2: Illustration of 2D histogram distribution.
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Figure 5.3: Spatial analysis for quantifying tumor regional distribution.
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Figure 5.4: Illustration of 3D histogram distribution.
FLAIR signal presumably representing necrosis. However, two additional sub-regions each with less water
and more apparent cellularity were also present.
5.6.3 Applying Spatial Analysis to Clinical Response
The two progressing groups were analyzed using 3D graphs that plotted the relative frequency of regions
with specific combinations of T1 post gadolinium signal and either FLAIR or T2-weighted signal. As
shown in Figure 5.3, the Group2 progressing tumors typically consisted of tumor habitats with high blood
flow and relatively high cell density. Group1 progressing tumors had increased regions of low blood flow.
Interestingly, while these often corresponded to high T2-weighted or FLAIR signals indicating necrosis,
regions with low blood flow and relatively high cell density were frequently present.
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5.6.4 Survival Group Prediction
Histogram variation features (as seen in Fig. 5.5) were examined using a two-tailed t test statistical anal-
ysis. In particular, we examined minimum and maximum, median, and possible outlier points of feature sets.
A two-tailed t test was performed on each derived feature between Group1 and Group2. A P value of less
than 0.05 was considered to have a significant difference. A significant difference was observed (P=0.04)
in the third feature D(Hi, T1)T1−T2(Hi is the ith histogram). Three features with marginal significance
were observed: D(Hi, T1)T1−FLAIR with 0.084, D(Hi, T2)T1−FLAIR with 0.104, and D(Hi, T2)T1−T2
with 0.07. There is no significant difference betweenD(Hi, T1)FLAIR−T2 andD(Hi, T2)FLAIR−T2, where
P values were 0.510 and 0.648, respectively.
To test the predicative capability, a binary classification scheme (i.e., Group1 and Group2) was formu-
lated. We used the machine learning classifier Support Vector Machines (SVM) to classify samples by using
a Gaussian kernel function to project the features into a higher-dimensional space. A leave-one-out cross
validation was used for performance evaluation. We reported results with the precise tumor boundary, the
eroded boundary, and the dilated boundary (as discussed in Section 4.4) in terms of the accuracy, speci-
ficity, and sensitivity values as shown in Figure 5.7. In addition, we show ROC curves in Figure 5.8 and the
associated area under curve (AUC) values are also given.
To further test the power of the proposed histogram-based feature, we evaluated prediction performance
using different data sources including a TCGA dataset and Moffitt dataset (as discussed in Chapter 6.2, only
pre-treatment cases were included). Validation from different sources is crucial in developing reproducible
analysis for the goal of translational health. In this experiment, we investigated the problem of survival
group prediction between two datasets. For the two datasets, the histogram-based features were computed
individually as discussed in Section 5.5.2. We first trained an SVM classifier using an RBF kernel on the
TCGA dataset (16 short term cases and 16 long term cases), and then tested on the Moffitt dataset (12 short
term and 10 long term cases) and vice versa. From Table 5.1, training with more samples from TCGA
resulted in better accuracy than training on the Moffitt dataset, and both results suggest good generality for
the proposed histogram-based features.
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Table 5.1: Prediction results from different data sources.
Training data Testing data Accuracy
TCGA datset Moffitt dataset 86.36%
Moffitt dataset TCGA datset 78.13%
5.7 Remarks
Multiple recent studies have demonstrated marked genetic heterogeneity between and within tumors.
This is typically ascribed to clonal evolution driven by random mutations. However, genetic mutations
simply represent one component (“a mechanism of inheritance ”) of Darwinian dynamics, which are ulti-
mately governed by phenotypic heterogeneity and variations in environmental selection forces [120]. In the
proposed model, intratumoral evolution is fundamentally governed by variations in environmental selection
forces which are largely dependent on local blood flow. Cancer cells must, therefore, adapt to different
environmental conditions associated with blood flow including variations in concentrations of oxygen, glu-
cose and serum growth factors. This suggests that only limited numbers of general adaptive strategies are
necessary, e.g., evolving the capacity to survive and proliferate in hypoxia. However, the phenotypic expres-
sion of those strategies is a much larger set of possibilities and the genetic pathway to those phenotypes is
likely very much larger [121]. Thus, the genetic variation among cancer cells could look chaotic even when
the underlying evolutionary dynamics are fairly straight-forward. This connection between environmen-
tal selection forces and phenotypic adaptations/genetic heterogeneity provides a theoretical bridge between
radiological imaging and cellular evolution within tumors. Thus, in [10], it hypothesized radiographic man-
ifestations of blood flow and interstitial edema can identify and map distinctive variations in environmental
selection forces (habitats) within each tumor.
To evaluate the potential role of habitat variations in survival, we arbitrarily divided our study group
into two groups based on survival time. This is obviously quite limited since there is no clear cutoff value
in the survival distribution. Furthermore, a large number of factors in addition to the tumor characteristics
may influence survival. In particular, some of the short term survivors may have died from complications of
therapy. Nevertheless, our results demonstrate that Group1 and Group2 progressing GBMs have distinctly
different patterns of vascularity and cellular density. As shown in Figure 5.3, GBMs consistently divide into
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5 MRI-defined combinations of blood flow and cellular density. At present, the underlying evolutionary
dynamics cannot be determined unambiguously. Clearly, the expected patterns are high blood flow and high
cell density and low blood flow with low cell density. The 3 additional regions of apparent miss-match
between blood flow and cellular density will require further investigation. The findings suggest two possible
ecologies including adaptive strategies in celluar evolution and temporal variations in regional perfusion.
As shown in Figure 5.4, we find Group2 tumors are more homogeneous with a dominant habitat in
which there is high blood flow and intermediate cell density. Group1 tumors, on the other hand, contain
relatively high volumes of low blood flow habitats that may have very low cell density indicating necrosis,
but often exhibit cell densities comparable to those seen in well perfused regions.
This suggests a clear need to further investigate the reason(s) these habitats confer a poor prognosis.
Since this is an initial retrospective study using a publically available data base, there are several limitations.
Lack of some clinical data (subtype and IDH1 status) and details of therapy limits our ability to divide the
dataset into more reasonable subsets. The analyzed cohort is relatively small and our results will need to be
confirmed in larger retrospective and prospective studies. Nevertheless, we show here that clinical imaging
can be used to gain insight into the evolutionary dynamics within tumors. Our results suggest that combina-
tions of sequences from standard MRI imaging can define spatially and physiologically distinct regions or
habitats within the ecology of GBMs and that this may be useful as a patient-specific prognostic biomarker.
Ultimately, many other combinations of imaging characteristics including other modalities such as PET
should be investigated and may provide greater information regarding intratumoral evolution. Finally, we
note that changes in intratumoral habitats during therapy may provide useful information regarding response
and the evolution of adaptive strategies.
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Figure 5.5: Illustration of feature variations from survival group1. On each box, the central red mark was the
median, and the edges of the box were the 25% and 75% of the distribution. Possible outliers were plotted
individually.
Figure 5.6: Illustration of feature variations from survival group2.
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Figure 5.7: Prediction performance.
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Figure 5.8: ROC results for survival group prediction.
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CHAPTER 6
HISTOGRAM-BASED ANALYSIS USING TEMPORAL TUMOR MRI
6.1 Note to the Reader
Part of this chapter was published in the proceedings of the 2015 SPIE Medical Imaging on Computer-
aided Diagnosis [137]. Permission is included in Appendix A.
6.2 Introduction
Brain tumor heterogeneity remains a challenge for probing brain cancer evolutionary dynamics. In light
of evolution, it is a priority to inspect the cancer system from a time-domain perspective since it explic-
itly tracks the dynamics of cancer variations. In this chapter, we study the problem of exploring brain
tumor heterogeneity from temporal clinical magnetic resonance imaging (MRI) data. Our goal is to dis-
cover evidence-based knowledge from such temporal imaging data, where multiple clinical MRI scans from
Glioblastoma multiforme (GBM) patients are generated during therapy. In particular, we propose a quan-
titative histogram-based approach that builds a prediction model to measure the difference in histograms
obtained from pre- and post-treatment. The study has the potential to significantly assist radiologists by
providing a metric to identify distinctive patterns within each tumor, which is crucial for the goal of pro-
viding patient-specific treatments. We examine the proposed approach for a practical application of clinical
survival group prediction. Experimental results show that our approach achieved 90.91% accuracy.
Glioblastoma Multiforme (GBM) is the most common malignant brain tumor and remains a uniformly
fatal disease. As the name (“multiforme”) implies, GBMs are extremely heterogeneous at cellular, molecular
and tissue scales. This variability is a significant barrier for understanding tumor dynamics and development
of successful therapy. Thus, it is not surprising that GBMs can have vastly diverse appearances before and
after therapy (as shown in Figure 6.1). To use this heterogeneous imaging data, it is necessary to develop
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methods that characterize and quantify spatial and temporal variations within each tumor. In particular,
temporal imaging data, drawing from sequential imaging in time, can explicitly track the cancer dynamics
as it responds and ultimately becomes resistant to therapy. Such temporal data, since it contains mineable
biological information, may serve as a tool for discovering meaningful patterns within these heterogeneous
images. Exploring cancer evolution from clinical imaging has shown promise: a recent study [10] demon-
strated that objective imaging features obtained from a quantitative analysis are powerful for cancer diagno-
sis. Following this idea, we ask the following specific questions: 1) Can temporal information derived from
clinical imaging be predictable based on combinations of MRI modalities? 2) Can we develop a biologically
interpretable metric to quantify different survival groups?
We examine brain tumor heterogeneity using temporal and spatial variations in clinical magnetic reso-
nance imaging (MRI) data. Prior studies of MRI have primarily investigated survival time prediction from
initial (pre-treatment) diagnostic scans [101], tumor type classification [35], and treatment decisions [85].
However, previous investigations have not explicitly examined changes in imaging data during therapy. In
practice, finding such data is relatively difficult because most GBM patients undergo surgical resection (or
at least debulking) which prevents comparison of pre- and post-therapy imaging. Here, we examine MRI
images in a novel cohort of patients with pathologically proven GBM receiving only radiation treatment
and chemotherapy (temzolomide). We build a prediction model that uses cumulative histograms of imaging
features obtained from pre- and post-treatment scans. Our goal is explicitly clinical and tests the hypothesis
that tumor imaging features prior to therapy or a change in these features during therapy can predict subse-
quent survival. In our initial analysis, to appropriately have balanced class samples, we divided the patients
into two cohorts: long term survivors who lived ≥ 340 days following initial diagnosis and short term sur-
vivors who live < 340 days. Notably, this is 15% different than the cutoff we previously used which may
have some effect by putting some people into the long term survivor group who really do not belong. The
balance is created to enhance the discrimination ability of the classifiers. We find that computed histogram
features (and, in particular, changes in these features during therapy) are predictive for clinical survival.
Furthermore, the visualization of derived difference histogram variations makes the approach appropriate
for practical clinical use.
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To the best of our knowledge, this is the first effort to quantitatively explore underlying information
from temporal imaging to predict brain cancer prognosis. Our results suggest it is possible to identify tumor
imaging characteristics that confer poor prognosis therapy, which could be used to develop individualized
therapy to apply more aggressive or alternative therapeutic strategies in such patients. Furthermore, the pro-
posed method shares a generalized property that can be easily extended to related computer-aided diagnosis
(CAD) problems.
6.3 Dataset
Following IRB approval, a dataset of 22 Glioblastoma (GBM) cases was collected from the H. Lee
Moffitt Cancer Research Center (as shown in Figure 6.1). All patients identifiers were removed. For each
patient, axial plane multi-modality scans were: (a) N = 4 MRI modalities, including T1-weighted, gadolin-
ium enhanced, T2-weighted, Fluid-attenuated Inversion Recovery (FLAIR), and the Apparent Diffusion
Map (ADM); and (b) t = 2 temporal sequences, including both pre- and post-treatment scans which were
obtained during therapy. T1-weighted images characterize the blood flow in brain tumors. T2-weighted and
FLAIR images measure interstitial edema (and, indirectly, cell volume). ADM measures water diffusion and
is a sensitive metric of cell density. To have a consistent delineation of the tumor boundary, the tumor was
outlined manually based on T1-weighted scans. Survival time was defined as the number of days between
the date of the initial diagnosis and the time of death. Following a previous study [108], which indicated that
the median survival of GBM is normally between 12 to 15 months, we also used an approximate median
survival time as the division criterion (340 days in this study): there were 12 short term cases (survival time
less than 340 days) and 10 long term cases (survival time greater than 340 days), with the mean and standard
deviation of 201 ± 89 days and 615 ± 442 days, respectively. All patients were treated with concomitant
radiation therapy and temozolomide after initial diagnostic scans while surgical intervention was restricted
to biopsy only. Pre-treatment scans were generated during the initial diagnosis, and post-treatment scans
were generated within 3 weeks of the completion of radiation treatment.
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(a) (b) (c) (d) 
Figure 6.1: Time-sequence tumor MRI examples. Axial T1-weighted postcontrast MR images showing
variations along with the radiation treatment. Two examples are given: (a) and (b) are pre-treatment and
post-treatment scans for a short term survivor; (c) and (d) are pre-treatment and post-treatment scans for a
long term survivor.
H1 = Histogram1
H2 = Histogram2
Difference of Histograms 
DH = H2 - H1
Tumor MRI
T1
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FLAIR
Joint Histogram Analysis Prediction Outputs
Pre-treatment
Post-treatment
Figure 6.2: Illustration of the proposed approach.
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6.4 Our Approach
We analyzed the data in two steps: 1) creation of a joint histogram from multi-modality imaging inputs.
2) learning a classifier for the clinical prediction task.
6.4.1 Pair-wise Histogram Representation
Ordinary 1-D histograms (a single channel input) consider a statistical frequency from one input modal-
ity, thus a potential correlation between different scans is entirely ignored. The proposed 2-D pairwise
histogram representation makes use of different modalities jointly. Therefore, resulting histograms have the
advantage of capturing statistical variance from dual modalities. Formally, for a pair of different modalities
M
(t)
i and M
(t)
j , i 6= j, at a particular time period t, where t = 1 indicates a pre-treatment scan; t = 2 indi-
cates a post-treatment scan. We computed a voxel-level joint frequency histogramH(t) = h(M
(t)
i ,M
(t)
j ) (as
shown in Figure 6.2). For each case, we initially built 10×10 bins (equivalent to 100 dimensions) to quantify
pairwise variations. The histogram captures bivariate frequencies of all intratumor voxels. Across different
cases, all computed frequency values were normalized into the range [0,1]. It is worth noting that, since our
histogram analysis is based on volumetric MRI data, we consider an entire distribution from the whole tu-
mor area rather than a slice-based regional statistic. Therefore, the volumetric histogram computation does
not require a rigorous registration for tumor slices in different MRI modalities.
6.4.2 Predictive Analysis
We studied the predictive power of the histogram features. At the training stage, we trained the feature
ranking classifier discussed earlier [101] (denoted as φ(.)). We chose this classifier due to its simplicity as it
enables us to observe individual features’ performance. In other words, we tested each bin in the difference
of histograms (DH). Also, other classifiers can be considered here for extended analysis. While a classifier is
created for each single feature (i.e. each bin in a histogram), we found that it gives us a perspective of the full
histogram rather than applying a feature dimension reduction technique (e.g., principal component analysis
(PCA) [138]) which seeks a reduced feature set in a transformed space that loses the original meaning of
underlying interpretable information. A full description of the approach is given below.
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Algorithm 2: Histogram Prediction Model
1: Input: Multi-modality Dataset M (t)i , where i and t denote an index and a period of a modality,
respectively.
2: for i← 1: N do
3: for j ← 1: N do
4: for t← 1: 2 do
5: Compute a joint histogram H(t) = h(M
(t)
i ,M
(t)
j ).
6: end for
7: Compute the difference of histograms DH(i,j) = H(1) −H(2).
8: Train a classifier φ(.) on DH(i,j).
9: Obtain the highest prediction accuracy p(i,j) = max{φ(DH(i,j))}.
10: end for
11: end for
6.5 Experiments
6.5.1 Prediction Performance
In this section, we examine our approach for survival group prediction. We used leave-one-out cross
validation for validating prediction performance. We considered 3 types of histogram computations, and
Tables 6.1 to 6.3 show the highest accuracy, G-mean, and F-measure obtained from derived histogram fea-
tures. Overall, we find that all types of histogram features contain rich predictive information for the survival
group prediction task. In particular, post-treatment histogram features show an improvement compared with
those from the pre-treatment histogram which is probably due to the influence of therapy. We report results
of accuracy, G-mean, and F-measure to evaluate prediction performance. The highest accuracy 90.91% was
obtained from the difference of histograms between T1-weighted and T2-weighted scans taken at different
times, suggesting a joint consideration from both periods is effective, which indeed reflects a shift of cancer
cell populations. Moreover, we compared the prediction performance obtained by the feature ranking classi-
fier [101] with a logistic regression classifier (during the stochastic gradient descent, the learning rate was c
= 0.0001) as shown in Tables 6.4 to 6.6. There is no significant difference being found using the McNemar’s
statistical test, but from accuracy results, the feature ranking classifier empirically outperforms the logistic
regression classifier.
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(a) T1 and FLAIR
(b)
(b) T1 and T2 (c) FLAIR and T2
(d) T1 and ADM (e) FLAIR and ADM (f) T1 and ADM
(g) T1 and FLAIR (h) T1 and T2 (i) FLAIR and T2
(j) T1 and ADM (k) FLAIR and ADM (l) T2 and ADM
Figure 6.3: Feature visualization from the difference histograms. Cold colors (e.g., blue) and hot colors
(e.g., red) indicate positive and negative changes, respectively. Subfigures (a) to (f) are from the short term
group; (g)-(l) are from the long term group (best view in color).
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6.5.2 Biological Interpretation
Our study demonstrated that changes in the intratumoral GBM habitats during therapy are highly pre-
dictive of subsequent survival. Interestingly, increases and decreases in tumor size, the traditional metric for
tumor response to therapy, was observed in both long- and short-surviving groups. As shown in Figure 6.3,
all tumors exhibited some habitat redistribution during therapy. By plotting the mean difference histograms
for both clinical groups, both the similarity and dissimilarity of each pair are considered. Differences in
trends between long term and short term responders are most evident in histograms (d) and (j) which com-
bines T1 post gadolinium images as a metric of relative vascularity and ADM images which are sensitive to
cell density. In short term survivors, there is a shift toward low T1 and high ADM habitats which have low
blood flow and low cell density. In long term survivors there is an opposite trend toward higher blood flow
(T1) and higher cell density (low ADM). A similar trend toward higher post treatment vascularity was also
observed in the T1 vs Flair images (histograms (a) and (g)). These results seem counter-intuitive. Conven-
tionally, maximum destruction of tumor cells is regarded as the most favorable outcome since it is assumed
this will result in the longest survival. However, our results demonstrate that the MRI habitats expected to
accompany maximum tumor cell death including increases in diffusion and decreases in blood flow were
actually predictive of relatively short survival time. On the other hand, increased numbers of habitats with
high vascularity and cell density during therapy were associated with longer survival times. While the mech-
anism for this unexpected finding remains to be determined, it is suggestive that vascular normalization may
play a significant role in the future work.
6.6 Remarks
We have proposed a novel histogram-based prediction model based on clinical MRI scans for exploring
brain tumor heterogeneity. We showed that multi-modality clinical imaging can be used to quantify the
underlying predictive characteristics and gain insight into the evolutionary dynamics within tumors. The
proposed work can be considered as a potential patient-specific prognostic biomarker that may be useful in
guiding therapeutic strategies. Experiments showed that the proposed approach was able to predict different
survival groups, and the difference histograms provide a visualization tool to interpret and understand cancer
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dynamics. In the future, we will investigate more quantitative features for discovering predictive biomarkers,
and we will analyze potential cellular and tissue properties with MRI tumor phenotypes.
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Table 6.1: Accuracy obtained from pre- and post-histogram features
Input pair modalities Pre histogram only Post histogram only Difference of histograms
T1-weighted and FLAIR 77.27 81.82 77.27
T1-weighted and T2-weighted 72.73 77.27 90.91
FLAIR and T2-weighted 68.18 81.82 77.27
T1-weighted and ADM 72.13 77.27 77.27
FLAIR and ADM 72.73 86.35 81.82
T2-wighted and ADM 72.73 81.82 77.27
Table 6.2: G-mean obtained from pre- and post-histogram features
Input pair modalities Pre histogram only Post histogram only Difference of histograms
T1-weighted and FLAIR 74.16 82.16 77.00
T1-weighted and T2-weighted 70.71 74.16 89.00
FLAIR and T2-weighted 67.08 82.16 77.46
T1-weighted and ADM 67.70 76.83 80.71
FLAIR and ADM 72.46 83.67 77.46
T2-wighted and ADM 67.70 81.65 77.46
Table 6.3: F-measure obtained from pre- and post-histogram features
Input pair modalities Pre histogram only Post histogram only Difference of histograms
T1-weighted and FLAIR 81.48 81.82 78.26
T1-weighted and T2-weighted 76.92 81.48 92.00
FLAIR and T2-weighted 63.16 81.20 78.00
T1-weighted and ADM 78.57 80.00 82.00
FLAIR and ADM 75.00 88.89 85.71
T2-wighted and ADM 78.57 80.00 78.26
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Table 6.4: Accuracy by a logistic regression classifier
Input pair modalities Pre histogram only Post histogram only Difference of histograms
T1-weighted and FLAIR 68.18 81.82 77.27
T1-weighted and T2-weighted 63.64 68.18 90.91
FLAIR and T2-weighted 68.18 72.73 81.82
T1-weighted and ADM 68.18 72.73 72.73
FLAIR and ADM 68.18 77.27 77.27
T2-wighted and ADM 59.09 63.64 77.27
Table 6.5: G-mean by a logistic regression classifier
Input pair modalities Pre histogram only Post histogram only Difference of histograms
T1-weighted and FLAIR 67.08 80.10 74.16
T1-weighted and T2-weighted 63.25 64.55 89.44
FLAIR and T2-weighted 68.31 72.46 70.71
T1-weighted and ADM 64.55 72.46 70.71
FLAIR and ADM 68.13 76.38 74.16
T2-wighted and ADM 59.16 63.25 77.46
Table 6.6: F-measure by a logistic regression classifier
Input pair modalities Pre histogram only Post histogram only Difference of histograms
T1-weighted and FLAIR 72.00 84.62 81.48
T1-weighted and T2-weighted 66.67 74.07 92.31
FLAIR and T2-weighted 69.57 70.00 84.62
T1-weighted and ADM 74.07 87.50 76.92
FLAIR and ADM 69.57 80.00 81.48
T2-wighted and ADM 60.87 60.00 78.26
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CHAPTER 7
IMBALANCED LEARNING FOR SURVIVAL GROUP PREDICTION
7.1 Note to the Reader
Part of this chapter was published in the proceedings of the 2015 SPIE Medical Imaging on Computer-
aided Diagnosis [139]. Permission is included in Appendix A.
7.2 Introduction
Accurate computer-aided prediction of survival time for brain tumor patients requires a thorough un-
derstanding of clinical data, since it provides useful prior knowledge for learning models. However, to
simplify the learning process, traditional settings often assume datasets with equally distributed classes,
which clearly does not reflect a typical distribution. Unfortunately, there are more short term survivors in
our case. More general, in other medical prediction problems, there may be many more normal or benign
samples. In this chapter, we investigate the problem of mining knowledge from an imbalanced dataset (i.e., a
skewed distribution) to predict survival time. In particular, we propose an algorithmic framework to predict
survival groups of brain tumor patients using multi-modality MRI data. Both an imbalanced distribution
and classifier design are jointly considered: 1) We used the Synthetic Minority Over-sampling Technique to
compensate for the imbalanced distribution; 2) A predictive linear regression model was adopted to learn
a pair of class-specific dictionaries, which were derived from the reformulated balanced data. We tested
the proposed framework using a dataset of 42 patients with Glioblastoma Multiforme (GBM) tumors whose
scans were obtained from the cancer genome atlas (TCGA). Experimental results showed that the proposed
method achieved 95.24% accuracy, which is higher than results from the balanced data set as presented and
is significantly higher than guessing the majority class (61.9%).
84
Brain tumor MR image analysis with its associated clinical application for diagnosis and treatment is an
evolving area in computer-aided diagnosis (CAD). Noninvasive clinical imaging enables us to view tumor
cell activities at a macroscopic scale. With a well-suited learning model, we are able to build a classifier
from imaging data to predict different types of clinical outputs. For example, the study [85] assessed brain
tumor radiotherapy treatment decisions with the Naive Bayes model and the study [35] used Support Vector
Machines (SVM) for brain tumor sub-type classification from MR images.
However, most of these prior studies have focused on the analysis of predictions based on either as-
sumed balanced datasets (i.e. balanced learning) or simply ignored the true clinical distribution, and hence
restricted their performance in a practical clinical decision-support system. These studies have not dealt
with the problem of predicting clinical events in a more difficult but practical setting—prediction from the
imbalanced datasets (i.e., imbalanced learning). The problem has not been thoroughly studied in clinical
brain image analysis, despite the fact that different techniques have been proposed in the data mining field.
Actually, imbalanced distributions are prevalent in the brain tumor patient population. Survival time is a typ-
ical example that illustrates the underlying phenomenon: Glioblastoma multiforme (GBM) is a highly lethal
neoplasm with a median survival of 12-15 months; only 2-5% of patients survived more than 3 years [140].
Additionally, the imbalanced setting poses a challenge for machine learning: ordinary classification algo-
rithms (e.g., SVM) can be hindered by class imbalances [141], where the prediction of small classes can
be overwhelmed by the majority class, because it is statistically better to be highly accurate on a very large
class. Therefore, the imbalanced brain tumor data requires a generalized model for effective prediction.
In this chapter, in contrast to the study of predicting with an equivalent number of samples for different
clinical classes, we make a step towards a real clinical scenario by exploring information from unequal class
distributed brain tumor data. As discussed in the prior section, we similarly cast the problem as a binary
class prediction problem. An accurate prediction model of patients’ survival time is of great clinical interest:
the importance of such a prediction is to provide better patient-specific treatment (e.g., end-of-life care), thus
to make more informed decisions and potentially help prolong patients’ lives. Prior approaches have been
proposed in the literature to predict survival groups in regards to tumor sub-regional variations [108], tumor
descriptors (e.g., tumor location and edema extent and imaging characteristics) [142], and spatial distance
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Figure 7.1: An overview of feature representation. The approach is designed to extract informative features
for brain tumor MRI data. (A) showed a contrast T1-weighted scan of a GBM patient.
measurement [32]. However, all these approaches did not consider the skewed distribution of survival
population.
We propose a novel algorithmic framework for imbalanced brain tumor MRI analysis to provide im-
proved survival time prediction. Specifically, both imbalanced distribution and classifier design are jointly
considered. First, to compensate for imbalance, we employ the Synthetic Minority Over-sampling Tech-
nique (SMOTE) [143] to form a new set of minority-class examples. Then, the features of the balanced
data sets were stacked into class-specific “dictionaries”. Using a linear regression model, a prediction was
made by comparing response vectors with the query sample. Conceptually, the proposed approach classifies
samples by searching for the most similar cases in a dictionary space, where it is analogous to a classical
k-nearest neighbor scheme which finds close cases in a feature space. Note that as pervasive class imbal-
anced data becomes more commonly explored for clinical cancer data, the proposed work can be extended
for more computer-aided diagnostic analyses.
7.3 Methodology
7.3.1 Feature Representation
We made use of multiple scale regional feature extraction and then a feature selection method to ob-
tain informative feature subsets. Multi-Scale Local Binary Patterns (MSLBP) [101] were used to extract
informative features to represent each patient (as shown in Figure 7.1). The basic idea was that niche tumor
regions may play a significant role in cancer diagnosis. From each modality (T1-weighted, FLAIR and
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Figure 7.2: LBP feature neighborhood structures.
T2-weithgted in our study), for voxels within the tumor, we begin with the computation of Local Binary
Patterns (LBP) [42] features in a window around each voxel of interest. In detail, given a tumor region, the
operator takes local neighborhood voxels around a specific central voxel (gc). By setting a threshold, its
neighborhood of voxels N within a circular radius of R (gp) are correspondingly converted into binary codes
(0s and 1s) that are further converted into a decimal value. Finally, the feature vector for learning is formed
based on a histogram from all obtained decimal values. The pair (P,R) is used to denote local neighborhood
structure, where P samplings are on a circle of radius of R. To fully capture underlying local variations, the
standard window was extended into different scales with (P,R)=(4,1),(8,1),(8,2),(8,3) and (16,2) as shown in
Figure 7.2. The formal LBP(P,R) is as described in Section 3.1.
Once a feature vector for a given data sample was obtained, we applied the Feature Ranking Model
(FRM) [101] for selecting feature subsets. FRM is a supervised feature selection model which measures
each single features predictive power in terms of finding the nearest mean neighbors, which is particularly
suitable for the binary class setting. To examine prediction performance, different numbers of features were
considered to form the feature subset (Sec. 3).
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Figure 7.3: Illustration of the proposed framework.
7.3.2 Over-sampling the Minority Class
In the presence of an imbalanced distribution between two classes, two major sampling techniques are
typically considered to realize a balanced distribution: under-sampling removes majority class data from the
original dataset; over-sampling appends new data to the original dataset. Considering the relatively small
size of the brain cancer dataset, to guarantee sufficient training data, we used an over-sampling technique—
Synthetic Minority Over-sampling Technique (SMOTE), to augment the existing minority class set to obtain
a balanced distribution. Formally, given a training set S with M examples, we defined a minority class set
Smin and a majority class set Smaj , so that Smaj ∪ Smin = {S} and Smaj ∩ Smin = {Φ}. The number of
samples were |Smaj | = n and |Smin| = p, where n > p, n + p = M. We seek a balanced representation
such that |Smaj | = |Smin|+ |A|, where A is an augmented sampling set. To obtain A, in particular, SMOTE
creates new samples xnew from the existing minority class set Smin by
xnew = xi + α|(xˆi − xi)|, xi ∈ Smin (7.1)
where α ∈ [0, 1] is a random scalar. We chose xˆi as the closest neighbor sample from any class to xi.
Finally, we were able to obtain reformulated data sets:
Sˆ1 = Smaj and Sˆ2 = Smin ∪ A (7.2)
As shown in Figure 7.3 with data sets Sˆ1 and Sˆ2, we formulated them into a class-specific dictionary regres-
sion model for the prediction task as described in Sec 2.3.
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7.3.3 Class-Specific Dictionary Regression
Dictionary learning is an emerging technique in machine learning which aims to build a discriminative
dictionary and classify unknown samples based on the dictionary reconstruction error. Following the recent
study [144], using a linear regression model for pattern recognition, we formulated survival prediction in
this regression model. An advantage of the algorithm is that it can be used in a parameter-free setting.
In the training stage, once balanced feature sets for both survival groups were obtained, we defined each
set as a class-level “dictionary”: Di = Sˆi ∈ Rm×n, i ∈ {1, 2}, where each dictionary consisted of n samples
with m features. We relied on the dictionary to essentially represent intrinsic class-specific information in
feature space. As it has been found that the collected set from the same class, in general, can be approximated
in a linear subspace [145]. Likewise, in study [90], it was shown that a sparse linear combination concept
could significantly improve prediction performance in pattern recognition. Thus, given an unknown sample
z ∈ Rm×1, we seek a linear combination from each class dictionary by
z = Diβi, where βi ∈ Rn×1 and i = 1, 2. (7.3)
By a standard least-squares method, an estimated βˆi can be obtained:
βˆi = (DTi Di)
−1DTi z (7.4)
Therefore, a response vector zˆi ∈ Rm×1, also known as a reconstructed vector, was computed by
zˆi = Diβˆi (7.5)
In the testing stage, after obtaining zˆi, the prediction was simply turned into a similarity matching
problem—finding a minimal distance between a query sample z and each response vector zˆi using the
Euclidean distance. Overall, the proposed framework is summarized in Algorithm 3.
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Algorithm 3: Class-specific Dictionary Regression from Imbalanced Data
1: Input: Given training samples Smaj ∈ Rm×n, Smin ∈ Rm×p with n > p. A test sample z ∈ Rm×1.
2: Use SMOTE to obtain reformulated sets Sˆ1 = Smaj and Sˆ2 = Smin ∪ A s.t. |A| = n− p.
3: Define balanced class dictionaries Di = Sˆi ∈ Rm×n, i ∈ {1, 2}.
4: Compute the estimated βˆi by least-squares estimation βˆi = (DTi Di)
−1DTi z.
5: Compute the response vector, zˆi = Diβˆi.
6: Euclidean distance calculation by di(z) = ||z − zˆi||.
7: Output: Identity(z) = argminidi(z).
7.4 Experiments
7.4.1 Data Acquisition and Evaluation
Glioblastoma multiforme (GBM) MRI scans of 42 patients were collected from the cancer genome
atlas (TCGA). In compliance with related regulations, all patient identifiers have been eliminated. The
data are post contrast T1-weighted, FLAIR and T2-weighted modalities all in the axial plane. The data
were 200mm×200mm, 220mm×220mm and 240mm×240mm field of view and 5mm slice thickness, with
256×256 image sizes (512×512 slices were resized into 256× 256). To obtain reliable performance, the
ground truth tumor boundary was manually identified with help from a radiologist. The clinical survival
time was defined as the number of days between the date of the initial pathological diagnosis and time
to death obtained from the patient demographics in the TCGA database. We used the MRI data which
were obtained at the initial diagnosis, thus the possible influence of the following clinical therapy was not
accounted for in our study. As discussed from the study [108], we also chose to approximately follow the
overall statistics [140], where a reported median value of survival time for GBMs was 12-15 months. In our
study, the patient cohort was initially divided into two groups: Group1 (survival time < 400 days, 26 cases)
and Group2 (survival time≥ 400 days, 16 cases), where the mean and standard deviation of each group were
160± 103 (days) and 846± 448 (days), respectively. Three evaluation metrics were used for measuring the
performance: Accuracy, F-measure and G-mean. We chose Group2 (long term cases) as the positive class
(Pc) and Group1 (short term cases) as the negative class (Nc). Based on the binary class confusion matrix
with True Positives (TP), False Positives (FP), False Negatives (FN) and True Negatives (TN), we have the
Precision = TPTP+FP and Recall =
TP
TP+FN. Thus, we made use of accuracy, G-mean, and F-measure to
evaluate prediction performance.
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Figure 7.4: Survival time distribution.
7.4.1.1 Experimental Results
A leave-one-out cross validation was used to evaluate the approach. Note that, to have a fair comparison,
augmented samples were completely excluded from the testing set. During the training stage, depending on
the number of training samples from both classes, augmented samples of the minority class were created:
|A| = |Smaj | − |Smin| (i.e, 25 − 16 = 9 or 26 − 15 = 11). Table 7.1 shows results on the dataset
with different feature subsets, where we empirically varied the most predictive 100, 120, 140, 160 and
180 features (denoted as Subsets1 to 5 in Table 1). The selected features were used to learn different
models for the prediction. As a baseline, without a sampling technique, we compared results with the
study [101], which used an SVM classifier for the prediction task. In addition, we compared our work with
two sampling-based approaches: 1) the EasyEnsemble approach [146], which learned multiple classifiers
using an under-sampling scheme (with a default parameter setting); 2) We also used SMOTE sampling with
SVM. It is noted that, due to the skewed distribution, the G-mean from study [101] was significantly lower:
it ultimately reduced to 0 with Subset5, in other words, all prediction outcomes were overwhelmed by the
negative class. Overall, the proposed approach showed stable and competitive results with all results above
90%.
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Table 7.1: Performance by different evaluation metrics (%)
Metrics Approaches Subset1 Subset2 Subset3 Subset4 Subset5
Accuracy The proposed method 95.24 92.86 95.24 95.24 95.24
EasyEnsemble [146] 80.95 71.43 78.57 76.19 66.67
SMOTE with SVM 83.33 80.95 73.81 73.81 76.19
SMOTE with Logistic Regression 88.10 90.48 90.48 92.86 92.86
SMOTE with KNN (n=1) 88.10 83.33 90.48 92.86 92.86
SVM [101] 88.10 85.71 66.67 64.29 61.90
G-mean The proposed method 94.94 91.72 93.54 93.54 93.54
EasyEnsemble [146] 81.01 72.06 79.06 75.96 65.78
SMOTE with SVM 84.92 82.77 75.00 75.00 77.06
SMOTE with Logistic Regression 82.92 86.60 90.14 90.14 90.14
SMOTE with KNN (n=1) 86.10 79.66 86.60 90.14 90.14
SVM [101] 89.07 86.05 52.58 34.67 0.00
F-measure The proposed method 96.15 94.34 96.30 96.30 96.30
EasyEnsemble [146] 84.00 75.00 81.63 80.00 72.00
SMOTE with SVM 85.11 82.61 76.60 76.60 79.17
SMOTE with Logistic Regression 92.13 92.86 92.86 94.55 94.55
SMOTE with KNN (n=1) 86.60 79.66 86.66 90.14 90.14
SVM [101] 89.80 88.00 76.67 76.92 76.47
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We further compared predicted outputs with survival ground truth in terms of the Kaplan-Meier survival
curves. In Figure 7.4, the dashed curves are predicted outputs obtained from the highest 95.24% classifier
using feature subset1. The predictive model can approximately fit the original distribution and the predicted
survival groups were significantly different (p value <0.00001).
7.5 Remarks
We proposed a novel framework for patient survival group prediction from imbalanced brain tumor
MR data. We used the SMOTE over-sampling scheme for balancing training data and the prediction was
made by a linear regression model from defined class-specific dictionaries. We made a step towards a real
clinical scenario by exploring information from unequally distributed brain tumor data. More generally,
with the guidance of different clinical data, the proposed framework can be used for other clinical prediction
applications.
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CHAPTER 8
CONCLUSIONS
This chapter summarizes the primary findings and results of this dissertation and includes a number of
ideas for the future research in quantitative cancer imaging.
8.1 Summary
• Chapter 2 presented related state-of-the-art techniques in computational models for image-guided
brain cancer analysis, which is playing an important role in clinical guidance and health care. Af-
ter a general description of brain tumor MRI assessment, it included studies from several important
computational components in image analysis. The most important contribution of Chapter 2 was a sys-
tematic presentation on integrating computational learning techniques with associated specific brain
cancer diagnosis problems, bridging the gap between different domains. The discussion allowed the
reader to choose the most appropriate approaches to evaluate different tasks.
• Chapter 3 presented a framework to study the local variation in brain tumor MRI. The motivation
was derived from biological knowledge that indicates the local environment is critical to maintain cell
survival through the delivery of signals by the so-called “niche” that directs cell differentiation and
proliferation. We made use of a multi-scale LBP feature extractor to capture brain tumor heterogeneity
and proposed a simple yet effective supervised feature selection model to specifically tackle the binary
survival group prediction problem. Our findings suggested that information gained from the T1-
weighed modality contributed significantly to differentiate survival groups.
• Chapter 4 presented a novel concept of tumor habitats to explicitly quantify tumor sub-regions. Tumor
is generally heterogeneous because it contains multiple regions with different imaging properties, but
each of these sub-regions may (or may not) be homogeneous. As a result, based on multi-modality
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MRI, we proposed a spatial mapping scheme to explicitly identify multiple distinct tumor sub-regions
which would facilitate observation and characterization of tumor evolution before and during therapy.
We examined performance of regional habitats by predicting clinical survival time in a cohort of
32 patients with malignant GBMs collected from The Cancer Genome Atlas (TCGA) database and
achieved a best prediction result of 87.50%. The potential clinical impact of the proposed work
includes development of analytic tools to support clinical decisions in patient-specific GBM treatment.
• Chapter 5 quantitatively assessed regional variations in blood flow and interstitial edema using com-
binations of MRI sequences and correlated these radiologically defined habitats with survival time in
patients with glioblastoma multiforme (GBM). Analysis of all tumors demonstrated 5 distinct combi-
nations of blood flow and cell density. Two groups of tumors showed distinctly different distributions
in these regions. Consistent combinations of blood flow and cellular density were found in MRIs
from GBMs. The presence of significant cell populations in poorly perfused environments is pre-
sumptive evidence of phenotypes that have successfully adapted to the environmental consequences
of hypo-perfusion. Radiologically defined ecological tumor analysis may provide valuable prognostic
and predictive biomarkers in GBM and other tumors.
• Chapter 6 proposed a histogram-based model to explore brain cancer evolutionary dynamics. From
a time-domain perspective, tumor MRI explicitly tracks the dynamics of cancer variations. The pro-
posed approach discovered evidence-based knowledge from such temporal imaging data, where multi-
ple clinical MRI scans from Glioblastoma multiforme (GBM) patients were generated during therapy.
The study could significantly assist radiologists by providing a metric to identify distinctive patterns
within each tumor, which is crucial for the goal of providing patient-specific treatments.The proposed
approach can be considered as a potential patient-specific prognostic biomarker that may be useful in
guiding therapeutic strategies. Experiments show that the proposed approach was able to effectively
predict different survival groups.
• Chapter 7 presented an algorithmic framework to tackled the skewed clinical data issue, mining
knowledge from an imbalanced dataset to predict survival groups. A key factor is that a thorough
understanding of clinical data would help build well-suited algorithms for specific diagnostic prob-
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lems. In the framework, both an imbalanced distribution and classifier design are jointly consid-
ered. We tested the proposed framework using a dataset of 42 patients with Glioblastoma Multiforme
(GBM) tumors whose scans were obtained from the cancer genome atlas (TCGA). Experimental re-
sults showed that the proposed method achieved 95.24% accuracy, suggesting the proposed model
was able to effectively learn useful predictive knowledge from the unequally distributed dataset.
8.2 Contribution
During my Ph.D. study, I have participated in multiple publications which are focused on quantitative
brain tumor modeling. A publication list is shown below.
1. Mu Zhou, Lawrence Hall, Dmitry Goldgof, Robin Russo, Yoganand Balagurunathan, Robert Gillies
and Robert Gatenby. “Radiologically Defined Ecological Dynamics and Clinical Outcomes in Glioblas-
toma Multiforme”, Journal of Translational Oncology, 7(1), 5-13, 2014.
2. Mu Zhou, Lawrence Hall, Dmitry Goldgof, Robert Gillies and Robert Gatenby. “Imbalanced Learning
for Clinical Survival Group Prediction of Brain Tumor Patients”, accepted, SPIE Medical Imaging
Conference, Orlando, FL, 2015.
3. Mu Zhou, Lawrence Hall, Dmitry Goldgof, Robert Gillies and Robert Gatenby. “Decoding Brain
Cancer Dynamics: A Quantitative Histogram-based Approach using Temporal MRI”, accepted, SPIE
Medical Imaging Conference, Orlando, FL, 2015.
4. Mu Zhou, Lawrence Hall, Dmitry Goldgof, Robert Gillies and Robert Gatenby. “Exploring Tumor
Heterogeneity for Survival Time Prediction”, Oral Presentation, In Proc. IEEE International Confer-
ence on Pattern Recognition (ICPR), Stockholm, Sweden, 2014. (oral presentation, acceptance rate
14%)
5. Mu Zhou, Lawrence Hall, Dmitry Goldgof, Robert Gatenby, Robert Gillies. “A Texture Feature
Ranking Model for Predicting Survival Time of Brain Tumor Patients”, In Proc. IEEE Conference on
System, Man and Cybernetic, Manchester, Manchester, UK, 2013. (oral presentation)
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6. Mu Zhou, Lawrence Hall, Dmitry Goldgof, Robert Gillies, Robert Gatenby. “Survival Time Predic-
tion of Patients with Glioblastoma Multiforme Tumors using Spatial Distance Measurement”, In Proc.
SPIE Medical Imaging Conference on Computer-Aided Diagnosis, Orlando, FL, 2013.
8.3 Future Work
Quantitative cancer imaging is a new area with numerous research opportunities. This section presents
several important problems and challenges in developing quantitative models using tumor imaging.
• Quantitative Cancer Imaging: Currently, research initiatives are either done qualitatively from radiol-
ogists or quantitatively from computer scientists, but rarely both. There is an inherent gap between
human experts’ experiences (e.g., tumor semantic features described from radiologists) and automated
intelligent techniques (e.g., learning models). The ability to effectively utilize knowledge from both
perspectives will largely empower the current disease prediction paradigm. For example, building
an interactive learning system will potentially improve treatment quality, leading to better decision-
making for patients. From machine learning, developing an active learning model will help improve
prediction performance by inviting human professionals (e.g., radiologists) into the loop with an in-
telligent computer program: with aid from human experts knowledge, such as identifying particular
data samples (e.g., selecting malignant tumors with high confidence); in return, such a process will
enable a learning algorithm to obtain a more accurate prediction.
• Large Scale Computational Modeling: “Big Data Analysis” is a rising topic that is permeating the
biomedical area with new opportunities. The term “Big Data Analysis” concerns mining useful infor-
mation from the large amounts of data currently being generated and stored as its core [147]. For ex-
ample, to explore a fundamental understanding of cancer, we are seeking comprehensive knowledge
about data heterogeneity in large volumes of clinical imaging and the resulting high-dimensional
quantitative features. Mining multi-modality heterogeneous health data provides an unprecedented
view of disease from a fusion-based analysis. Such big data in clinical cancer imaging can contribute
to a data-driven selection of high-dimensional quantitative features and increasing number of volumes
of imaging data. Analyzing such big data requires high-throughput pipelines that are able to provide
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bottom-up models including feature extraction approaches, statistical analysis, and data sharing sys-
tems. Also, the fast explosion of clinical and radiological MRI data pose new challenges for the design
of robust systems on imaging data management and processing. Multiple data sources (e.g., medical
institutes) and various data types (e.g., multi-modality imaging data) make data sharing and collec-
tive administration a complex problem. To address the challenge, instead of conventional computing
techniques, scalable approaches are essential for mining knowledge from heterogeneous cancer data.
It is promising to develop scalable approaches to the interpretation (e.g., disease condition and tumor
response) from the growing volumes of available clinical data. Furthermore, it is a priority to develop
learning models that not only find underlying feature correlations for a disease, but also the potential
cause and effect, leading to improvements in patient-specific treatment. Notably, efficient data inte-
gration from multi-sources would largely benefit the development of translational health data mining,
however, limited studies have addressed related problems. The concept is not limited to the topic of
cancer imaging, but can be generalized into the broad field of health informatics.
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Appendix A: Permission For Reuse and Data Summary
Below is permission for the use of material in Chapter 3.
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Appendix A (Continued)
Below is permission for the use of material in Chapter 4.
112
Appendix A (Continued)
Below is permission for the use of material in Chapter 5.
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